Human NK Cell Education by Inhibitory Receptors for M

**Immunity** 

25, 331-342

DOI: 10.1016/j.immuni.2006.06.013

Citation Report

#	Article	IF	Citations
1	Natural killer cells and malaria. Immunological Reviews, 2006, 214, 251-263.	2.8	41
2	Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics, 2006, 59, 1-15.	1.2	114
3	NK Cells and Cancer. Journal of Immunology, 2007, 178, 4011-4016.	0.4	248
4	Deficient Major Histocompatibility Complex-Linked Innate Murine Cytomegalovirus Immunity in MA/My.L-H2 b Mice and Viral Downregulation of H-2 k Class I Proteins. Journal of Virology, 2007, 81, 229-236.	1.5	35
5	Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands. Journal of Immunology, 2007, 179, 5977-5989.	0.4	188
6	CD56brightCD16â° Killer Ig-Like Receptorâ° NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation. Journal of Immunology, 2007, 178, 4947-4955.	0.4	430
7	Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood, 2007, 109, 4296-4305.	0.6	140
8	Differential natural killer cell–mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. Journal of Experimental Medicine, 2007, 204, 3027-3036.	4.2	413
9	Relevance of C1 and C2 Epitopes for Hemopoietic Stem Cell Transplantation: Role for Sequential Acquisition of HLA-C-Specific Inhibitory Killer Ig-Like Receptor. Journal of Immunology, 2007, 178, 3918-3923.	0.4	75
10	KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro. Journal of Immunology, 2007, 179, 854-868.	0.4	178
11	A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood, 2007, 110, 578-586.	0.6	202
12	Defective cytotoxic lymphocyte degranulation in syntaxin-11–deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood, 2007, 110, 1906-1915.	0.6	272
13	Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value Blood, 2007, 110, 433-440.	0.6	550
14	Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15. Immunity, 2007, 26, 503-517.	6.6	769
15	Ready for Prime Time: NK Cell Priming by Dendritic Cells. Immunity, 2007, 26, 385-387.	6.6	64
16	Good News, Bad News for Missing-Self Recognition by NK Cells: Autoimmune Control but Viral Evasion. Immunity, 2007, 26, 549-551.	6.6	12
17	HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends in Immunology, 2007, 28, 437-441.	2.9	32
18	Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opinion on Biological Therapy, 2007, 7, 599-615.	1.4	22

#	ARTICLE	IF	CITATIONS
19	Phenotypic Studies of Natural Killer Cell Subsets in Human Transporter Associated with Antigen Processing Deficiency. PLoS ONE, 2007, 2, e1033.	1.1	11
20	Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. European Journal of Immunology, 2007, 37, 780-787.	1.6	60
21	Germ-line and rearrangedTcrd transcription distinguishbona fide NK cells and NK-like γδ T cells. European Journal of Immunology, 2007, 37, 1442-1452.	1.6	72
23	Regulation of natural killer cell activity. Current Opinion in Immunology, 2007, 19, 46-54.	2.4	51
24	Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nature Genetics, 2007, 39, 733-740.	9.4	691
25	Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nature Genetics, 2007, 39, 1092-1099.	9.4	207
26	Prospects for the use of NK cells in immunotherapy of human cancer. Nature Reviews Immunology, 2007, 7, 329-339.	10.6	481
27	Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nature Reviews Immunology, 2007, 7, 703-714.	10.6	362
28	Killer cell immunoglobulinâ€like receptors on NK cells: the how, where and why. International Journal of Immunogenetics, 2008, 35, 1-8.	0.8	67
29	NK Cells Rapidly Reject Allogeneic Bone Marrow in the Spleen Through a Perforin―and Ly49Dâ€Dependent, but NKG2D―ndependent Mechanism. American Journal of Transplantation, 2007, 7, 1884-1896.	2.6	40
30	Global Unresponsiveness as a Mechanism of Natural Killer Cell Tolerance in Mixed Xenogeneic Chimeras. American Journal of Transplantation, 2007, 7, 2090-2097.	2.6	25
31	Stromal-cell regulation of natural killer cell differentiation. Journal of Molecular Medicine, 2007, 85, 1047-1056.	1.7	32
32	Natural killer cells: from CD3â^'NKp46+ to post-genomics meta-analyses. Current Opinion in Immunology, 2007, 19, 365-372.	2.4	117
33	Line of attack: NK cell specificity and integration of signals. Current Opinion in Immunology, 2008, 20, 344-352.	2.4	183
34	Role of KIRs and KIR ligands in hematopoietic transplantation. Current Opinion in Immunology, 2008, 20, 581-587.	2.4	75
35	Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Seminars in Immunopathology, 2008, 30, 489-503.	2.8	27
36	Role of natural killer cells in HIV pathogenesis. Current HIV/AIDS Reports, 2008, 5, 44-50.	1.1	12
37	KIRigami: the case for studying NK cell receptors in SIV+ macaques. Immunologic Research, 2008, 40, 235-243.	1.3	6

3

#	Article	IF	Citations
38	Natural killer cells infiltrating human nonsmallâ€eell lung cancer are enriched in CD56 <sup>bright</sup> CD16 <sup>â^'</sup> cells and display an impaired capability to kill tumor cells. Cancer, 2008, 112, 863-875.	2.0	321
39	Autologous and allogeneic HLA KIR ligand environments and activating KIR control KIR NK ell functions. European Journal of Immunology, 2008, 38, 3474-3486.	1.6	42
40	Tolerance and reactivity of NK cells: Two sides of the same coin?. European Journal of Immunology, 2008, 38, 2930-2933.	1.6	11
41	Beyond licensing and disarming: A quantitative view on NKâ€eell education. European Journal of Immunology, 2008, 38, 2934-2937.	1.6	53
42	Effect of Low-Dose IL-2 Immunotherapy on Frequency and Phenotype of Regulatory T Cells and NK Cells in HIV/HCV-Coinfected Patients. AIDS Research and Human Retroviruses, 2008, 24, 52-61.	0.5	17
43	Human NK cells: from HLA class lâ€specific killer Igâ€like receptors to the therapy of acute leukemias. Immunological Reviews, 2008, 224, 58-69.	2.8	112
44	Regulation of NK cell responsiveness to achieve selfâ€tolerance and maximal responses to diseased target cells. Immunological Reviews, 2008, 224, 85-97.	2.8	115
45	Negative signaling by inhibitory receptors: the NK cell paradigm. Immunological Reviews, 2008, 224, 70-84.	2.8	310
46	Immunoreceptor tyrosineâ€based inhibition motifs: a quest in the past and future. Immunological Reviews, 2008, 224, 11-43.	2.8	315
47	REVIEW ARTICLE: NK Cell Tolerance and the Maternal–Fetal Interface. American Journal of Reproductive Immunology, 2008, 59, 371-387.	1.2	69
48	Combination of KIR and HLA gene variants augments the risk of developing birdshot chorioretinopathy in HLA-A*29-positive individuals. Genes and Immunity, 2008, 9, 249-258.	2.2	44
49	NK cells and cancer immunosurveillance. Oncogene, 2008, 27, 5932-5943.	2.6	572
50	Functions of natural killer cells. Nature Immunology, 2008, 9, 503-510.	7.0	3,070
51	Mistaken notions about natural killer cells. Nature Immunology, 2008, 9, 481-485.	7.0	37
52	NK cells at the interface between innate and adaptive immunity. Cell Death and Differentiation, 2008, 15, 226-233.	5.0	291
53	Self-tolerance of Human Natural Killer Cells Lacking Self-HLA-specific Inhibitory Receptors. Scandinavian Journal of Immunology, 2008, 67, 218-229.	1.3	9
54	Natural Killer Cell Receptor Repertoire and Their Ligands, and the Risk of CMV Infection After Kidney Transplantation. American Journal of Transplantation, 2008, 8, 2674-2683.	2.6	83
55	Use of natural killer cells as immunotherapy for leukaemia. Best Practice and Research in Clinical Haematology, 2008, 21, 467-483.	0.7	35

#	ARTICLE	IF	Citations
56	Humanized Immune System (HIS) Mice as a Tool to Study Human NK Cell Development. Current Topics in Microbiology and Immunology, 2008, 324, 109-124.	0.7	14
57	The Killer Immunoglobulin-Like Receptor (KIR) Group A Haplotype is Associated With Bronchiolitis Obliterans Syndrome After Lung Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, 995-1001.	0.3	24
58	Inhibitory Receptor Signaling via Tyrosine Phosphorylation of the Adaptor Crk. Immunity, 2008, 29, 578-588.	6.6	95
59	NK receptor interactions with MHC class I molecules in pregnancy. Seminars in Immunology, 2008, 20, 317-320.	2.7	92
60	The Yin and Yang of HLA and KIR in human disease. Seminars in Immunology, 2008, 20, 343-352.	2.7	334
61	NK gene complex dynamics and selection for NK cell receptors. Seminars in Immunology, 2008, 20, 361-368.	2.7	29
62	KIR-HLA intercourse in HIV disease. Trends in Microbiology, 2008, 16, 620-627.	3.5	129
63	Natural killer cells: Detectors of stress. International Journal of Biochemistry and Cell Biology, 2008, 40, 2335-2340.	1.2	18
64	Immunotherapy for Pediatric Cancer. Biology of Blood and Marrow Transplantation, 2008, 14, 33-43.	2.0	8
65	NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells, Molecules, and Diseases, 2008, 40, 84-90.	0.6	134
66	Human natural killer cells. Blood, 2008, 112, 461-469.	0.6	1,572
67	NK cells and surveillance in humans. Reproductive BioMedicine Online, 2008, 16, 192-201.	1.1	14
68	Roles and mechanism of natural killer cells in clinical and experimental transplantation. Expert Review of Clinical Immunology, 2008, 4, 79-91.	1.3	5
69	Synergistic Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a Stronger Receptor for HLA-C Than KIR2DL3. Journal of Immunology, 2008, 180, 3969-3979.	0.4	350
70	FcÎ <sup>3</sup> RIIIa Expression Is Not Increased on Natural Killer Cells Expressing the FcÎ <sup>3</sup> RIIIa-158V Allotype. Cancer Research, 2008, 68, 976-980.	0.4	45
71	Lineage-Specific Transition of Histone Signatures in the Killer Cell Ig-Like Receptor Locus from Hematopoietic Progenitor to NK Cells. Journal of Immunology, 2008, 180, 418-425.	0.4	51
72	Profiling killers; unravelling the pathways of human natural killer cell function. Briefings in Functional Genomics & Proteomics, 2008, 7, 8-16.	3.8	3
73	A novel subset of NK cells expressing high levels of inhibitory FcγRIIB modulating antibody-dependent function. Journal of Leukocyte Biology, 2008, 84, 1511-1520.	1.5	36

#	Article	IF	Citations
74	A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. Aids, 2008, 22, 1487-1491.	1.0	125
75	Strategies of Natural Killer (NK) Cell Recognition and Their Roles in Tumor Immunosurveillance. , 2008, , 37-81.		1
76	HLA alleles determine differences in human natural killer cell responsiveness and potency. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3053-3058.	3.3	239
77	Complete Characterization of Killer Ig-Like Receptor (KIR) Haplotypes in Mauritian Cynomolgus Macaques: Novel Insights into Nonhuman Primate KIR Gene Content and Organization. Journal of Immunology, 2008, 181, 6301-6308.	0.4	78
78	Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A $\langle i \rangle$ KIR $\langle i \rangle$ Haplotype. Journal of Immunology, 2008, 181, 6010-6019.	0.4	99
79	Lysis of Endogenously Infected CD4+ T Cell Blasts by rIL-2 Activated Autologous Natural Killer Cells from HIV-Infected Viremic Individuals. PLoS Pathogens, 2008, 4, e1000101.	2.1	88
80	HLA Class I Molecules Regulate IFN- $\hat{I}^3$ Production Induced in NK Cells by Target Cells, Viral Products, or Immature Dendritic Cells through the Inhibitory Receptor ILT2/CD85j. Journal of Immunology, 2008, 181, 2368-2381.	0.4	45
81	Continuous engagement of a self-specific activation receptor induces NK cell tolerance. Journal of Experimental Medicine, 2008, 205, 1829-1841.	4.2	147
83	NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood, 2008, 111, 1428-1436.	0.6	185
84	Temporal, quantitative, and functional characteristics of single-KIR–positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood, 2008, 112, 3488-3499.	0.6	113
85	Enhanced NK-cell development and function in BCAP-deficient mice. Blood, 2008, 112, 131-140.	0.6	29
86	A role for interleukin-12/23 in the maturation of human natural killer and CD56+ T cells in vivo. Blood, 2008, 111, 5008-5016.	0.6	57
87	MHC class l–specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood, 2008, 112, 2369-2380.	0.6	268
88	How killers kill. Blood, 2008, 112, 213-213.	0.6	7
89	Host genetic determinants of HIV pathogenesis: an immunologic perspective. Current Opinion in HIV and AIDS, 2008, 3, 342-348.	1.5	13
90	Variable interactions of recipient killer cell immunoglobulin-like receptors with self and allogenic human leukocyte antigen class I ligands may influence the outcome of solid organ transplants. Current Opinion in Organ Transplantation, 2008, 13, 430-437.	0.8	10
91	Baseline Levels of Influenza-Specific CD4 Memory T-Cells Affect T-Cell Responses to Influenza Vaccines. PLoS ONE, 2008, 3, e2574.	1.1	48
92	The Fathers of Italian Histology. European Journal of Histochemistry, 2009, 51, 1.	0.6	5

#	Article	IF	Citations
93	Evidence for Natural Killer Cell–Mediated Protection from Metastasis Formation in Uveal Melanoma Patients. , 2009, 50, 2888.		26
94	Natural Killer Lysis Receptor (NKLR)/NKLR-Ligand Matching as a Novel Approach for Enhancing Anti-Tumor Activity of Allogeneic NK Cells. PLoS ONE, 2009, 4, e5597.	1.1	23
95	Probing Natural Killer Cell Education by Ly49 Receptor Expression Analysis and Computational Modelling in Single MHC Class I Mice. PLoS ONE, 2009, 4, e6046.	1.1	26
96	Development of Functional Human NK Cells in an Immunodeficient Mouse Model with the Ability to Provide Protection against Tumor Challenge. PLoS ONE, 2009, 4, e8379.	1.1	22
97	HLA Class I Subtype-Dependent Expansion of KIR3DS1 <sup>+</sup> and KIR3DL1 <sup>+</sup> NK Cells during Acute Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2009, 83, 6798-6805.	1.5	170
98	Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18692-18697.	3.3	109
99	Killer Ig-Like Receptor ( <i>KIR</i> ) Genotype Predicts the Capacity of Human KIR-Positive CD56dim NK Cells to Respond to Pathogen-Associated Signals. Journal of Immunology, 2009, 182, 6426-6434.	0.4	42
100	Killer Ig-Like Receptor Ligand Mismatch Directs NK Cell Expansion In Vitro. Journal of Immunology, 2009, 183, 4502-4508.	0.4	17
101	Chimpanzees Use More Varied Receptors and Ligands Than Humans for Inhibitory Killer Cell Ig-Like Receptor Recognition of the MHC-C1 and MHC-C2 Epitopes. Journal of Immunology, 2009, 182, 3628-3637.	0.4	49
102	IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. Journal of Experimental Medicine, 2009, 206, 25-34.	4.2	481
103	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12879-12884.	3.3	61
104	NK Cell Responsiveness Is Tuned Commensurate with the Number of Inhibitory Receptors for Self-MHC Class I: The Rheostat Model. Journal of Immunology, 2009, 182, 4572-4580.	0.4	234
105	Natural Killer Cell Receptors in Human Immunodeficiency Virus Infection: Pathways to Protection or Doors to Disappointment?. Current HIV Research, 2009, 7, 487-496.	0.2	1
106	<i>KIR</i> and <i>HLA</i> Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma. Clinical Cancer Research, 2009, 15, 7330-7334.	3.2	117
107	Cutting Edge: Killer Ig-Like Receptors Mediate "Missing Self―Recognition In Vivo. Journal of Immunology, 2009, 182, 2569-2572.	0.4	9
108	The Lytic Potential of Human Liver NK Cells Is Restricted by Their Limited Expression of Inhibitory Killer Ig-Like Receptors. Journal of Immunology, 2009, 183, 1789-1796.	0.4	55
109	Quantification of IFN- $\hat{l}^3$ produced by human purified NK cells following tumor cell stimulation: Comparison of three IFN- $\hat{l}^3$ assays. Journal of Immunological Methods, 2009, 350, 89-96.	0.6	12
110	Immunotherapy of cancer. European Journal of Pharmacology, 2009, 625, 41-54.	1.7	85

#	Article	IF	CITATIONS
111	Education of hyporesponsive NK cells by cytokines. European Journal of Immunology, 2009, 39, 2548-2555.	1.6	38
112	Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Current Opinion in Immunology, 2009, 21, 525-530.	2.4	137
113	Distinct Conformations of Ly49 Natural Killer Cell Receptors Mediate MHC Class I Recognition in Trans and Cis. Immunity, 2009, 31, 598-608.	6.6	52
114	Distribution of Several Activating and Inhibitory Receptors on CD3â°CD16+ NK Cells and Their Correlation with NK Cell Function in Healthy Individuals. Journal of Membrane Biology, 2009, 230, 113-123.	1.0	39
115	Impaired immune function in Gulf War Illness. BMC Medical Genomics, 2009, 2, 12.	0.7	70
116	Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clinical and Experimental Immunology, 2009, 157, 325-331.	1.1	66
117	NK cells in HIVâ€1 infection: evidence for their role in the control of HIVâ€1 infection. Journal of Internal Medicine, 2009, 265, 29-42.	2.7	163
118	KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia, 2009, 23, 492-500.	3.3	236
119	HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nature Genetics, 2009, 41, 1290-1294.	9.4	265
120	Crosstalk between components of the innate immune system: promoting antiâ€microbial defenses and avoiding immunopathologies. Immunological Reviews, 2009, 227, 129-149.	2.8	64
121	A Role for cis Interaction between the Inhibitory Ly49A Receptor and MHC Class I for Natural Killer Cell Education. Immunity, 2009, 30, 337-347.	6.6	111
122	Home Schooling of NK Cells. Immunity, 2009, 30, 313-315.	6.6	0
123	NK cell education: not an on-off switch but a tunable rheostat. Trends in Immunology, 2009, 30, 143-149.	2.9	218
124	Demethylating treatment suppresses natural killer cell cytolytic activity. Molecular Immunology, 2009, 46, 2064-2070.	1.0	51
125	Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I:C-augmented human PBMCs. Molecular Immunology, 2009, 46, 3108-3116.	1.0	31
126	Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy. Journal of Translational Medicine, 2009, 7, 82.	1.8	68
127	Chapter 2 Natural Killer Cell Tolerance. Advances in Immunology, 2009, 101, 27-79.	1.1	120
128	Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood, 2009, 113, 3119-3129.	0.6	343

#	Article	IF	CITATIONS
129	Natural killer cells: integrating diversity with function. Immunology, 2009, 126, 449-457.	2.0	107
130	HLA-C Matching and Liver Transplants: Donor-Recipient Genotypes Influence Early Outcome and CD8+KIR2D+ T-Cells Recuperation. Transplantation, 2009, 88, S54-S61.	0.5	21
131	The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element. Blood, 2009, 113, 3245-3253.	0.6	46
132	Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell–depleted allogeneic hematopoietic cell transplantation. Blood, 2009, 113, 3875-3884.	0.6	115
133	The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood, 2009, 113, 2434-2441.	0.6	218
134	KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood, 2009, 114, 95-104.	0.6	93
135	Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood, 2009, 114, 2657-2666.	0.6	228
136	Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells. Blood, 2009, 114, 2667-2677.	0.6	363
137	"Self―reflection by KIR. Blood, 2009, 114, 2-3.	0.6	9
138	Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood, 2009, 114, 4108-4116.	0.6	84
139	Natural killer cells and tumor control. Current Opinion in Hematology, 2010, 17, 514-521.	1.2	10
140	Biology and clinical effects of natural killer cells in allogeneic transplantation. Current Opinion in Oncology, 2010, 22, 130-137.	1.1	42
141	Natural Killer Cell Activation in the Lung Allograft Early Posttransplantation. Transplantation, 2010, 89, 756-763.	0.5	19
142	NK cells expressing inhibitory KIR for non–self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood, 2010, 115, 2686-2694.	0.6	79
143	Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood, 2010, 115, 2167-2176.	0.6	711
144	Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood, 2010, 115, 1166-1174.	0.6	256
145	CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood, 2010, 116, 1299-1307.	0.6	249
146	NK-cell education: KIR-S come into play. Blood, 2010, 115, 1110-1111.	0.6	2

#	Article	IF	CITATIONS
147	Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood, 2010, 116, 4158-4167.	0.6	102
148	CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood, 2010, 116, 3865-3874.	0.6	636
149	Distribution of killer cell immunoglobulin-like receptors (KIR) and their HLA-C ligands in two Iranian populations. Immunogenetics, 2010, 62, 65-73.	1.2	34
150	Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells. Clinical Immunology, 2010, 135, 26-32.	1.4	19
151	B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Experimental Hematology, 2010, 38, 213-221.	0.2	35
152	Tolerant and diverse natural killer cell repertoires in the absence of selection. Experimental Cell Research, 2010, 316, 1309-1315.	1.2	12
153	Consistent beneficial effects of killer cell immunoglobulinâ€ike receptor 2DL3 and group 1 human leukocyte antigen  following exposure to hepatitis C virus. Hepatology, 2010, 51, 1168-1175.	3.6	145
154	Murine CXCR3 <sup>+</sup> CD27 <sup>bright</sup> NK cells resemble the human CD56 <sup>bright</sup> NKâ€cell population. European Journal of Immunology, 2010, 40, 1428-1439.	1.6	54
155	Genetic variation, $Fcl^3$ receptors, KIRs and infection: the evolution of autoimmunity. Current Opinion in Immunology, 2010, 22, 715-722.	2.4	23
156	Synergistic Signals for Natural Cytotoxicity Are Required to Overcome Inhibition by c-Cbl Ubiquitin Ligase. Immunity, 2010, 32, 175-186.	6.6	109
157	Primateâ€specific regulation of natural killer cells. Journal of Medical Primatology, 2010, 39, 194-212.	0.3	64
158	The tortoise and the hare: slowly evolving Tâ€cell responses take hastily evolving KIR. Immunology, 2010, 131, 301-309.	2.0	21
159	Natural killer cells in human autoimmune diseases. Immunology, 2010, 131, 451-458.	2.0	125
160	'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nature Immunology, 2010, 11, 321-327.	7.0	239
161	Do NK cells always need a license to kill?. Nature Immunology, 2010, 11, 279-280.	7.0	15
162	Current perspectives of natural killer cell education by MHC class I molecules. Nature Reviews Immunology, 2010, 10, 724-734.	10.6	195
163	Natural killer cells: alloreactive effects in hematopoietic stem cell transplantation. ISBT Science Series, 2010, 5, 282-287.	1.1	0
164	Memoryâ€ike responses of natural killer cells. Immunological Reviews, 2010, 235, 297-305.	2.8	64

#	Article	IF	CITATIONS
165	Cytotoxic immunological synapses. Immunological Reviews, 2010, 235, 24-34.	2.8	188
166	Natural killer alloeffector responses in haploidentical hemopoietic stem cell transplantation to treat high-risk leukemias. Tissue Antigens, 2010, 75, 103-109.	1.0	18
167	African Americans exhibit a predominant allele in the midst of extensive KIR2DL1 allelic diversity. Tissue Antigens, 2010, 76, 31-4.	1.0	5
168	NK Cell Terminal Differentiation: Correlated Stepwise Decrease of NKG2A and Acquisition of KIRs. PLoS ONE, 2010, 5, e11966.	1.1	179
169	Innate immune natural killer cells and their role in HIV and SIV infection. HIV Therapy, 2010, 4, 483-504.	0.6	13
170	MHC class l–deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class l–sufficient environment. Journal of Experimental Medicine, 2010, 207, 2073-2079.	4.2	173
171	Natural Killer Cell Protocols. Methods in Molecular Biology, 2010, , .	0.4	4
172	Natural killer cells in cancer. , 2010, , 55-64.		0
173	HIV Protective KIR3DL1 and HLA-B Genotypes Influence NK Cell Function Following Stimulation with HLA-Devoid Cells. Journal of Immunology, 2010, 184, 2057-2064.	0.4	88
174	Combined Genotypic and Phenotypic Killer Cell Ig-Like Receptor Analyses Reveal KIR2DL3 Alleles Displaying Unexpected Monoclonal Antibody Reactivity: Identification of the Amino Acid Residues Critical for Staining. Journal of Immunology, 2010, 185, 433-441.	0.4	32
175	MHC class I D <sup>k</sup> expression in hematopoietic and nonhematopoietic cells confers natural killer cell resistance to murine cytomegalovirus. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8754-8759.	3.3	25
176	Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. Journal of Leukocyte Biology, 2010, 88, 1119-1130.	1.5	77
177	NK cell KIR heterogeneity and evolution. , 2010, , 79-94.		4
178	Human natural killer cell development. , 2010, , 113-122.		1
179	Identification of natural killer cells in tissues and their isolation. , 2010, , 417-431.		0
180	Natural killer cells and allogeneic haematopoietic cell transplantation. , 2010, , 543-553.		1
181	Clinical trials of NK cells for cancer. , 2010, , 555-570.		2
182	Interleukin-22 (IL-22) Production by Pulmonary Natural Killer Cells and the Potential Role of IL-22 during Primary Influenza Virus Infection. Journal of Virology, 2010, 84, 7750-7759.	1.5	90

#	Article	IF	CITATIONS
183	Coevolution of Killer Cell Ig-Like Receptors with HLA-C To Become the Major Variable Regulators of Human NK Cells. Journal of Immunology, 2010, 185, 4238-4251.	0.4	73
184	Effects of MHC Class I Alleles on Licensing of Ly49A+ NK Cells. Journal of Immunology, 2010, 184, 3424-3432.	0.4	57
185	Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells. Journal of Leukocyte Biology, 2010, 88, 905-912.	1.5	46
186	Mind the Gap: Lack of Association between KIR3DL1*004/HLAâ€Bw4â€"Induced Natural Killer Cell Function and Protection from HIV Infection. Journal of Infectious Diseases, 2010, 202, S356-S360.	1.9	27
187	The impact of KIR2DS4 alleles and the expression of KIR in the development of acute GVHD after unrelated allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2010, 45, 1435-1441.	1.3	29
188	Dissecting Human NK Cell Development and Differentiation. , 2010, , 39-61.		2
189	NK Cell Education and CIS Interaction Between Inhibitory NK Cell Receptors and Their Ligands. , 2010, , 93-108.		1
190	Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy, 2010, 12, 750-763.	0.3	83
191	Natural Killer Cells*., 2010,, 53-85.		1
192	Signal Transduction During Activation and Inhibition of Natural Killer Cells. Current Protocols in Immunology, 2010, 90, Unit 11.9B.	3.6	118
193	Natural killer cells in atopic and autoimmune diseases of the skin. Journal of Allergy and Clinical Immunology, 2010, 125, 60-68.	1.5	81
194	Activation of Natural Killer Cells During Acute Infection With Hepatitis C Virus. Gastroenterology, 2010, 138, 1536-1545.	0.6	162
195	Re-educating natural killer cells. Journal of Experimental Medicine, 2010, 207, 2049-2052.	4.2	30
196	Extending killer Ig-like receptor function: from HLA class I recognition to sensors of microbial products. Trends in Immunology, 2010, 31, 289-294.	2.9	24
197	CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends in Immunology, 2010, 31, 401-406.	2.9	220
198	Natural Killer Cells: Tolerance to Self and Innate Immunity to Viral Infection and Malignancy. Biology of Blood and Marrow Transplantation, 2010, 16, S97-S105.	2.0	23
199	HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2010, 16, S57-S63.	2.0	37
200	Expansion of NKG2Aâ^LIR1â^ Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 469-481.	2.0	7

#	Article	IF	CITATIONS
201	Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptor–Negative Natural Killer Cells after NKG2A and LIR-1 Blockade. Biology of Blood and Marrow Transplantation, 2010, 16, 612-621.	2.0	87
202	NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biology of Blood and Marrow Transplantation. 2010. 16. 565-586.	2.0	107
203	Natural Killer Cell Education and Tolerance. Cell, 2010, 142, 847-856.	13.5	353
204	Functional Analysis of Human NK Cells by Flow Cytometry. Methods in Molecular Biology, 2010, 612, 335-352.	0.4	122
205	Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood, 2010, 116, 3853-3864.	0.6	654
206	Developmental stages and pathways of NK cell maturation. , 2010, , 3-24.		1
207	The Tumor Microenvironment. , 2010, , .		6
208	Dissecting CD56dim human NK cells. Blood, 2010, 116, 3689-3691.	0.6	170
209	Killer Ig–like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood, 2011, 117, 764-771.	0.6	218
210	The CD6 Scavenger Receptor Is Differentially Expressed on a CD56 <sup>dim</sup> Natural Killer Cell Subpopulation and Contributes to Natural Killer-Derived Cytokine and Chemokine Secretion. Journal of Innate Immunity, 2011, 3, 420-434.	1.8	44
212	Self MHC class I–licensed NK cells enhance adaptive CD8 T-cell viral immunity. Blood, 2011, 117, 5133-5141.	0.6	33
213	KIR/HLA: Genetic Clues for a Role of NK Cells in the Control of HIV. Advances in Experimental Medicine and Biology, 2011, 780, 27-36.	0.8	10
214	Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, 2011, 3, 1445-1459.	1.0	134
215	NK cells and their receptors during viral infections. Immunotherapy, 2011, 3, 1075-1086.	1.0	25
216	Natural Killer Cell Licensing During Viral Infection. Advances in Experimental Medicine and Biology, 2011, 780, 37-44.	0.8	9
217	Innate or Adaptive Immunity? The Example of Natural Killer Cells. Science, 2011, 331, 44-49.	6.0	2,234
219	Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection. Trends in Immunology, 2011, 32, 219-224.	2.9	26
220	Unifying concepts of MHC-dependent natural killer cell education. Trends in Immunology, 2011, 32, 364-372.	2.9	241

#	ARTICLE	IF	CITATIONS
221	Divergences in KIR2D+ natural killer and KIR2D+CD8+ T-cell reconstitution following liver transplantation. Human Immunology, 2011, 72, 229-237.	1.2	5
222	Assessment of physiologic natural killer cell cytotoxicity in vitro. Human Immunology, 2011, 72, 1007-1012.	1.2	12
223	Natural Killer Cells from HIV Infected Slow Progressors Who Carry the Protective HLA-B*27 Allele and Inhibitory KIR3DL1 Receptors Have Elevated Poly-Functional Potential Compared to Bw6 Homozygotes. , $2011, $ , .		0
225	Human diversity of killer cell immunoglobulin-like receptors and disease. The Korean Journal of Hematology, 2011, 46, 216.	0.7	72
226	Natural Killer Cells: From Basic Research to Treatments. Frontiers in Immunology, 2011, 2, 18.	2.2	47
227	The Interaction with H-2Dd in cis is Associated with a Conformational Change in the Ly49A NK Cell Receptor. Frontiers in Immunology, 2011, 2, 55.	2.2	10
228	Copy Number Variation of KIR Genes Influences HIV-1 Control. PLoS Biology, 2011, 9, e1001208.	2.6	132
229	Human NK Cells Differ More in Their KIR2DL1-Dependent Thresholds for HLA-Cw6-Mediated Inhibition than in Their Maximal Killing Capacity. PLoS ONE, 2011, 6, e24927.	1.1	21
230	Characterization of Natural Killer Cell Phenotype and Function during Recurrent Human HSV-2 Infection. PLoS ONE, 2011, 6, e27664.	1.1	56
231	Natural killer cells in spontaneous control of HIV infection. Current Opinion in HIV and AIDS, 2011, 6, 208-213.	1.5	22
232	Activating Signals Dominate Inhibitory Signals in CD137L/IL-15 Activated Natural Killer Cells. Journal of Immunotherapy, 2011, 34, 187-195.	1.2	47
233	Host genetic polymorphisms associated with innate immune factors and HIV-1. Current Opinion in HIV and AIDS, 2011, 6, 427-434.	1.5	37
234	NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood, 2011, 117, 1021-1029.	0.6	67
235	Analyses of HLA-C–specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood, 2011, 117, 98-107.	0.6	101
236	Impact of $\hat{l}^2$ 2 integrin deficiency on mouse natural killer cell development and function. Blood, 2011, 117, 2874-2882.	0.6	24
237	Inhibitory receptors specific for MHC class I educate murine NK cells but not CD8 $\hat{l}\pm\hat{l}\pm$ intestinal intraepithelial T lymphocytes. Blood, 2011, 118, 339-347.	0.6	15
238	Neonatal NK-cell repertoires are functionally, but not structurally, biased toward recognition of self HLA class I. Blood, 2011, 117, 5152-5156.	0.6	42
239	Natural killer cell subsets in man and rodents. Tissue Antigens, 2011, 78, 81-88.	1.0	56

#	ARTICLE	IF	CITATIONS
240	Donor and recipient HLA/KIR genotypes do not predict liver transplantation outcome. Transplant International, 2011, 24, 932-942.	0.8	13
241	Transcription specificity of the class Ib genes <i>SLAâ€6</i> , <i>SLAâ€7</i> and <i>SLAâ€8</i> of the swine major histocompatibility complex and comparison with class Ia genes. Animal Genetics, 2011, 42, 510-520.	0.6	8
242	Use of NK cell activity in cure by transplant. British Journal of Haematology, 2011, 155, 14-29.	1.2	110
243	Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology, 2011, 132, 315-325.	2.0	234
244	Control of epithelial cell function by interleukin-22-producing RORγt+ innate lymphoid cells. Immunology, 2011, 132, 453-465.	2.0	96
245	The emerging role of HLA-C in HIV-1 infection. Immunology, 2011, 134, 116-122.	2.0	55
246	DCs and NK cells: critical effectors in the immune response to HIV-1. Nature Reviews Immunology, 2011, 11, 176-186.	10.6	177
247	NK cell development, homeostasis and function: parallels with CD8+ T cells. Nature Reviews Immunology, 2011, 11, 645-657.	10.6	557
248	Interleukin 10 decreases MICA expression on melanoma cell surface. Immunology and Cell Biology, 2011, 89, 447-457.	1.0	26
249	Versatility in NK cell memory. Immunology and Cell Biology, 2011, 89, 327-329.	1.0	21
250	Activating and inhibitory receptors of natural killer cells. Immunology and Cell Biology, 2011, 89, 216-224.	1.0	426
251	Human NK receptors: From the molecules to the therapy of high risk leukemias. FEBS Letters, 2011, 585, 1563-1567.	1.3	36
252	Molecular determinant-based typing of KIR alleles and KIR ligands. Clinical Immunology, 2011, 138, 274-281.	1.4	25
253	Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression. Clinical Cancer Research, 2011, 17, 6287-6297.	3.2	377
254	Expansion of CD56-Negative, CD16-Positive, KIR-Expressing Natural Killer Cells after T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Acta Haematologica, 2011, 126, 13-20.	0.7	20
255	NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood, 2011, 118, 2784-2792.	0.6	117
256	Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood, 2011, 117, 4284-4292.	0.6	104
257	IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Research and Treatment, 2011, 130, 465-475.	1.1	45

#	ARTICLE	IF	CITATIONS
258	Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunology, Immunotherapy, 2011, 60, 1195-1205.	2.0	118
259	Mechanisms of NK cell activation: CD4+ T cells enter the scene. Cellular and Molecular Life Sciences, 2011, 68, 3457-3467.	2.4	33
260	Cis–trans interactions of cell surface receptors: biological roles and structural basis. Cellular and Molecular Life Sciences, 2011, 68, 3469-3478.	2.4	40
261	Insights into NK cell biology from human genetics and disease associations. Cellular and Molecular Life Sciences, 2011, 68, 3479-3493.	2.4	46
262	A distinct subset of human NK cells expressing HLAâ€DR expand in response to ILâ€2 and can aid immune responses to BCG. European Journal of Immunology, 2011, 41, 1924-1933.	1.6	80
263	NK cells: immune cross-talk and therapeutic implications. Immunotherapy, 2011, 3, 1143-1166.	1.0	88
264	An Early HIV Mutation within an HLA-B*57-Restricted T Cell Epitope Abrogates Binding to the Killer Inhibitory Receptor 3DL1. Journal of Virology, 2011, 85, 5415-5422.	1.5	57
265	Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-11.	3.0	157
266	Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-7.	3.0	122
267	Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. Journal of Experimental Medicine, 2011, 208, 13-21.	4.2	414
268	miR-150 regulates the development of NK and iNKT cells. Journal of Experimental Medicine, 2011, 208, 2717-2731.	4.2	202
269	Role of alloreactive KIR2DS1+ NK cells in haploidentical hematopoietic stem cell transplantation. Journal of Leukocyte Biology, 2011, 90, 661-667.	1.5	21
270	Interactions of NK Cell Receptor KIR3DL1*004 with Chaperones and Conformation-Specific Antibody Reveal a Functional Folded State As Well As Predominant Intracellular Retention. Journal of Immunology, 2011, 186, 62-72.	0.4	35
271	Ly49-Dependent NK Cell Licensing and Effector Inhibition Involve the Same Interaction Site on MHC Ligands. Journal of Immunology, 2011, 186, 3911-3917.	0.4	16
272	Molecular Mechanisms of Natural Killer Cell Activation. Journal of Innate Immunity, 2011, 3, 216-226.	1.8	194
273	Killer immunoglobulin-like receptors (KIRs) and HLA-C allorecognition patterns implicative of dominant activation of natural killer cells contribute to recurrent miscarriages. Human Reproduction, 2011, 26, 491-497.	0.4	92
274	Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells. Journal of Immunology, 2011, 187, 3546-3554.	0.4	40
275	Confinement of Activating Receptors at the Plasma Membrane Controls Natural Killer Cell Tolerance. Science Signaling, 2011, 4, ra21.	1.6	122

#	ARTICLE	IF	CITATIONS
276	NK Cell Receptor/H2-Dk–Dependent Host Resistance to Viral Infection Is Quantitatively Modulated by H2q Inhibitory Signals. PLoS Genetics, 2011, 7, e1001368.	1.5	9
277	Significant Association of KIR2DL3-HLA-C1 Combination with Cerebral Malaria and Implications for Co-evolution of KIR and HLA. PLoS Pathogens, 2012, 8, e1002565.	2.1	56
278	Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Frontiers in Immunology, 2012, 3, 336.	2.2	94
279	Ligand specificity of Killer cell Immunoglobulin-like Receptors: a brief history of KIR. Frontiers in Immunology, 2012, 3, 394.	2.2	3
280	Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension. Circulation, 2012, 126, 1099-1109.	1.6	99
281	Natural killer cell alloreactivity 10 years later. Current Opinion in Hematology, 2012, 19, 421-426.	1.2	43
282	Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 800-811.	1.8	171
283	Innate Immune Control of HIV. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007070-a007070.	2.9	62
284	Natural Killer Cells in Pulmonary Arterial Hypertension. Circulation, 2012, 126, 1020-1022.	1.6	1
285	Identification of human NK cells that are deficient for signaling adaptor $FcR^{\hat{1}3}$ and specialized for antibody-dependent immune functions. International Immunology, 2012, 24, 793-802.	1.8	158
286	Skewing of the NK Cell Repertoire by MHC Class I via Quantitatively Controlled Enrichment and Contraction of Specific Ly49 Subsets. Journal of Immunology, 2012, 188, 2218-2226.	0.4	48
287	HIV Infection Abrogates the Functional Advantage of Natural Killer Cells Educated through KIR3DL1/HLA-Bw4 Interactions To Mediate Anti-HIV Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2012, 86, 4488-4495.	1.5	50
288	Frequent and Strong Antibody-Mediated Natural Killer Cell Activation in Response to HIV-1 Env in Individuals with Chronic HIV-1 Infection. Journal of Virology, 2012, 86, 6986-6993.	1.5	37
289	Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. Antibodies, 2012, 1, 149-171.	1.2	36
290	A 17q12 Allele Is Associated with Altered NK Cell Subsets and Function. Journal of Immunology, 2012, 188, 3315-3322.	0.4	24
291	Mouse NK cell–mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. Blood, 2012, 119, 1590-1598.	0.6	45
292	A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood, 2012, 120, 4317-4323.	0.6	247
293	Toward a prime-boost regime for NK cells?. Blood, 2012, 120, 4663-4664.	0.6	0

#	Article	IF	CITATIONS
294	Super-resolution imaging of remodeled synaptic actin reveals different synergies between NK cell receptors and integrins. Blood, 2012, 120, 3729-3740.	0.6	52
295	Natural killer cells in hepatitis C virus infection. Expert Review of Clinical Immunology, 2012, 8, 775-788.	1.3	9
296	Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells. Immunogenetics, 2012, 64, 739-745.	1.2	27
297	The impact of HLA-C matching depends on the C1/C2 KIR ligand status in unrelated hematopoietic stem cell transplantation. Immunogenetics, 2012, 64, 879-885.	1.2	17
298	IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Breast Cancer Research and Treatment, 2012, 136, 659-671.	1.1	47
299	Enhanced mesenchymal stromal cell recruitment via natural killer cells by incorporation of inflammatory signals in biomaterials. Journal of the Royal Society Interface, 2012, 9, 261-271.	1.5	53
300	Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cellular and Molecular Immunology, 2012, 9, 310-320.	4.8	60
301	Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. Journal of Clinical Investigation, 2012, 122, 3260-3270.	3.9	190
302	The role of natural killer cells in immunity against multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1666-1676.	0.6	63
303	Natural Killer Cell Tolerance: Control by Self or Self-Control?. Cold Spring Harbor Perspectives in Biology, 2012, 4, a007229-a007229.	2.3	24
304	Comments on Type I bare lymphocyte syndrome. Immunology Letters, 2012, 143, 218-219.	1.1	4
305	The Adaptor Protein Crk Controls Activation and Inhibition of Natural Killer Cells. Immunity, 2012, 36, 600-611.	6.6	74
306	NK Cellsâ€"From Bench to Clinic. Biology of Blood and Marrow Transplantation, 2012, 18, S2-S7.	2.0	58
307	NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Current Opinion in Immunology, 2012, 24, 239-245.	2.4	176
308	NK/DC Crosstalk in Anti-viral Response. Advances in Experimental Medicine and Biology, 2012, 946, 295-308.	0.8	36
309	Clinical Production and Therapeutic Applications of Alloreactive Natural Killer Cells. Methods in Molecular Biology, 2012, 882, 491-507.	0.4	11
310	Overview of the Killer Cell Immunoglobulin-Like Receptor System. Methods in Molecular Biology, 2012, 882, 391-414.	0.4	53
311	Protocol for the Clonal Analysis of NK Cell Effector Functions by Multi-parameter Flow Cytometry. Methods in Molecular Biology, 2012, 903, 381-392.	0.4	10

#	Article	IF	Citations
312	STAT Transcription Factors: Controlling All Aspects of NK Cell Biology. , 2012, , 187-204.		0
313	Immunogenetics. Methods in Molecular Biology, 2012, , .	0.4	7
314	Tuning of Natural Killer Cell Reactivity by NKp46 and Helios Calibrates T Cell Responses. Science, 2012, 335, 344-348.	6.0	190
315	The role of natural killer cells in autoimmune blistering diseases. Autoimmunity, 2012, 45, 44-54.	1.2	21
316	Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics. Antibodies, 2012, 1, 88-123.	1.2	5
317	Diagnosis of Sexually Transmitted Diseases. Methods in Molecular Biology, 2012, , .	0.4	1
318	Influence of Cytokines on HIV-Specific Antibody-Dependent Cellular Cytotoxicity Activation Profile of Natural Killer Cells. PLoS ONE, 2012, 7, e38580.	1.1	22
319	Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Advances in Virology, 2012, 2012, 1-14.	0.5	20
320	Molecular mechanisms of natural killer cell regulation. Frontiers in Bioscience - Landmark, 2012, 17, 1418.	3.0	16
321	The role of natural killer cells in hematopoietic stem cell transplantation. Annals of Medicine, 2012, 44, 130-145.	1.5	13
322	Targeting natural killer cells and natural killer T cells in cancer. Nature Reviews Immunology, 2012, 12, 239-252.	10.6	707
323	Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis. Journal of Experimental Medicine, 2012, 209, 565-580.	4.2	199
324	Killerâ€eell immunoglobulinâ€ike receptors and malaria caused by <i>Plasmodium falciparum</i> in The Gambia. Tissue Antigens, 2012, 79, 104-113.	1.0	23
325	Inhibitory Killer Immunoglobulin-like receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected slow progressors. Clinical Immunology, 2012, 143, 246-255.	1.4	14
326	NK cells in human disease: An evolving story. Clinical Immunology, 2012, 143, 203-206.	1.4	9
327	Signatures of historical demography and pathogen richness on MHC class I genes. Immunogenetics, 2012, 64, 165-175.	1.2	26
328	Natural killer cell biology: An update and future directions. Journal of Allergy and Clinical Immunology, 2013, 132, 536-544.	1.5	321
329	Large Spectrum of HLA-C Recognition by Killer Ig–like Receptor (KIR)2DL2 and KIR2DL3 and Restricted C1 Specificity of KIR2DS2: Dominant Impact of KIR2DL2/KIR2DS2 on KIR2D NK Cell Repertoire Formation. Journal of Immunology, 2013, 191, 4778-4788.	0.4	81

#	Article	IF	Citations
330	Immunogenetics of <scp>HIV</scp> disease. Immunological Reviews, 2013, 254, 245-264.	2.8	128
331	Immunological Sculpting. , 2013, , 115-127.		3
332	Both the nature of KIR3DL1 alleles and the KIR3DL1/S1 allele combination affect the KIR3DL1 NK ell repertoire in the French population. European Journal of Immunology, 2013, 43, 1085-1098.	1.6	26
333	Natural killer cells in human autoimmune disorders. Arthritis Research and Therapy, 2013, 15, 216.	1.6	126
334	Distribution of Killer cell immunoglobulin like receptor genes in end stage renal disease among North Indian population. Human Immunology, 2013, 74, 1339-1345.	1.2	16
335	Differential Expression of the Ly49GB6, but Not the Ly49GBALB, Receptor Isoform during Natural Killer Cell Reconstitution after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1446-1452.	2.0	3
336	The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Research Reviews, 2013, 12, 1069-1078.	5.0	228
337	Cytomegalovirus (CMV)-dependent and -independent changes in the aging of the human immune system: A transcriptomic analysis. Experimental Gerontology, 2013, 48, 305-312.	1.2	15
338	Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses. Vaccine, 2013, 31, 5506-5517.	1.7	17
339	Cellular therapy of cancer with natural killer cells—where do we stand?. Cytotherapy, 2013, 15, 1185-1194.	0.3	34
340	Natural killer cells in liver disease. Hepatology, 2013, 57, 1654-1662.	3.6	237
341	Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition. Annual Review of Immunology, 2013, 31, 227-258.	9.5	1,012
342	NK cell-based immunotherapy for malignant diseases. Cellular and Molecular Immunology, 2013, 10, 230-252.	4.8	518
343	Natural killer cells in graft-versus-host disease and graft-versus-leukemia. , 2013, , 327-356.		0
344	Tissueâ€specific effector functions of innate lymphoid cells. Immunology, 2013, 139, 416-427.	2.0	37
346	DAP12 impacts trafficking and surface stability of killer immunoglobulin-like receptors on natural killer cells. Journal of Leukocyte Biology, 2013, 94, 301-313.	1.5	13
347	Tuning the threshold of natural killer cell responses. Current Opinion in Immunology, 2013, 25, 53-58.	2.4	81
348	Utilization of mouse models to decipher natural killer cell biology and potential clinical applications. Hematology American Society of Hematology Education Program, 2013, 2013, 227-233.	0.9	24

#	Article	IF	CITATIONS
349	Therapeutic applications: natural killer cells in the clinic. Hematology American Society of Hematology Education Program, 2013, 2013, 247-253.	0.9	77
351	Memory NK cells: why do they reside in the liver?. Cellular and Molecular Immunology, 2013, 10, 196-201.	4.8	26
352	The role of KIR genes and ligands in leukemia surveillance. Frontiers in Immunology, 2013, 4, 27.	2.2	25
353	Virus Encoded MHC-Like Decoys Diversify the Inhibitory KIR Repertoire. PLoS Computational Biology, 2013, 9, e1003264.	1.5	20
354	The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses. Frontiers in Immunology, 2012, 3, 402.	2.2	15
355	Cutting Edge: NK Cell Licensing Modulates Adhesion to Target Cells. Journal of Immunology, 2013, 191, 3981-3985.	0.4	50
356	Education of Murine NK Cells Requires Both <i>ci&gt;</i> and <i>trans</i> Recognition of MHC Class I Molecules. Journal of Immunology, 2013, 191, 5044-5051.	0.4	39
357	Irradiated and Activated Autologous PBMCs Induce Expansion of Highly Cytotoxic Human NK Cells In Vitro. Journal of Immunotherapy, 2013, 36, 373-381.	1.2	24
358	Epstein-Barr Virus Coinfection in Children Boosts Cytomegalovirus-Induced Differentiation of Natural Killer Cells. Journal of Virology, 2013, 87, 13446-13455.	1.5	80
359	HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus–Related Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 5465-5473.	3.2	46
360	Signatures of Human NK Cell Development and Terminal Differentiation. Frontiers in Immunology, 2013, 4, 499.	2.2	131
361	Natural killer cell licensing in mice with inducible expression of MHC class I. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4232-7.	3.3	36
362	NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand. Journal of Immunology, 2013, 190, 4650-4660.	0.4	55
363	Contrasting Effects of Anti-Ly49A Due to MHC Class IcisBinding on NK Cell–Mediated Allogeneic Bone Marrow Cell Resistance. Journal of Immunology, 2013, 191, 688-698.	0.4	8
364	Effect of Donor KIR2DL1 Allelic Polymorphism on the Outcome of Pediatric Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 3782-3790.	0.8	57
365	Genetic dissection of NK cell responses. Frontiers in Immunology, 2013, 3, 425.	2.2	5
366	HLA Reduces Killer Cell Ig-like Receptor Expression Level and Frequency in a Humanized Mouse Model. Journal of Immunology, 2013, 190, 2880-2885.	0.4	15
367	Amplified NKG2C+ NK Cells in Cytomegalovirus (CMV) Infection Preferentially Express Killer Cell Ig-like Receptor 2DL: Functional Impact in Controlling CMV-Infected Dendritic Cells. Journal of Immunology, 2013, 191, 2708-2716.	0.4	55

#	Article	IF	CITATIONS
368	Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry. Science Translational Medicine, 2013, 5, 208ra145.	5.8	491
369	Characterization of a novel NKG2D and NKp46 double-mutant mouse reveals subtle variations in the NK cell repertoire. Blood, 2013, 121, 5025-5033.	0.6	31
370	Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. Blood, 2013, 122, 1518-1521.	0.6	22
371	Clinical Relevance of Natural Killer Cells Following Hematopoietic Stem Cell Transplantation. Journal of Cancer, 2013, 4, 25-35.	1.2	42
372	Differentiation and functional regulation of human fetal NK cells. Journal of Clinical Investigation, 2013, 123, 3889-3901.	3.9	108
373	Epigenetic regulation of NK cell differentiation and effector functions. Frontiers in Immunology, 2013, 4, 55.	2.2	71
374	Natural Killer Cell Inhibitory Receptor Expression in Humans and Mice: A Closer Look. Frontiers in Immunology, 2013, 4, 65.	2.2	34
375	Impact of HCMV Infection on NK Cell Development and Function after HSCT. Frontiers in Immunology, 2013, 4, 458.	2.2	41
376	The Yin-Yang of KIR3DL1/S1: Molecular Mechanisms and Cellular Function. Critical Reviews in Immunology, 2013, 33, 203-218.	1.0	26
377	Natural Killer Cell and Cancer Immunotherapy. Hanyang Medical Reviews, 2013, 33, 59.	0.4	2
378	NK Cell Phenotypic and Functional Heterogeneities and Molecular Mechanisms of Cytotoxicity. Critical Reviews in Oncogenesis, 2014, 19, 21-45.	0.2	6
379	Ly49 Receptors: Innate and Adaptive Immune Paradigms. Frontiers in Immunology, 2014, 5, 145.	2.2	71
380	Inhibitory Receptor-Mediated Regulation of Natural Killer Cells. Critical Reviews in Immunology, 2014, 34, 455-465.	1.0	10
381	The AP-2 Clathrin Adaptor Mediates Endocytosis of an Inhibitory Killer Cell Ig-like Receptor in Human NK Cells. Journal of Immunology, 2014, 193, 4675-4683.	0.4	2
382	Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5688-96.	3.3	65
383	Both plasmacytoid dendritic cells and monocytes stimulate natural killer cells early during human herpes simplex virus type $1$ infections. Immunology, 2014, 143, 588-600.	2.0	33
384	Quantifying the Protection of Activating and Inhibiting NK Cell Receptors during Infection with a CMV-Like Virus. Frontiers in Immunology, 2014, 5, 20.	2.2	11
385	Natural Killer Cell Function and Dysfunction in Hepatitis C Virus Infection. BioMed Research International, 2014, 2014, 1-9.	0.9	14

#	Article	IF	CITATIONS
386	The adaptor protein Crk in immune response. Immunology and Cell Biology, 2014, 92, 80-89.	1.0	32
387	NK Cell Activation in Human Hantavirus Infection Explained by Virus-Induced IL-15/IL15Rα Expression. PLoS Pathogens, 2014, 10, e1004521.	2.1	43
388	HIV Protective KIR3DL1/S1-HLA-B Genotypes Influence NK Cell-Mediated Inhibition of HIV Replication in Autologous CD4 Targets. PLoS Pathogens, 2014, 10, e1003867.	2.1	62
389	Specific Dysregulation of IFNî <sup>3</sup> Production by Natural Killer Cells Confers Susceptibility to Viral Infection. PLoS Pathogens, 2014, 10, e1004511.	2.1	13
390	Improving the Outcome of Leukemia by Natural Killer Cell-Based Immunotherapeutic Strategies. Frontiers in Immunology, 2014, 5, 95.	2.2	42
391	Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica, 2014, 99, 836-847.	1.7	160
392	Advances in Tumor Immunology and Immunotherapy. , 2014, , .		2
393	Tracing dynamic expansion of human ⟨scp⟩NK⟨/scp⟩â€eell subsets by highâ€eesolution analysis of ⟨scp⟩KIR⟨/scp⟩ repertoires and cellular differentiation. European Journal of Immunology, 2014, 44, 2192-2196.	1.6	32
394	Notch Signaling at Later Stages of NK Cell Development Enhances KIR Expression and Functional Maturation. Journal of Immunology, 2014, 193, 3344-3354.	0.4	51
395	Phenotypic and Functional Activation of Hyporesponsive KIRnegNKG2Aneg Human NK-Cell Precursors Requires IL12p70 Provided by Poly(I:C)-Matured Monocyte-Derived Dendritic Cells. Cancer Immunology Research, 2014, 2, 1000-1010.	1.6	5
396	Radiation therapy combined with <i>Listeria monocytogenes </i> based cancer vaccine synergize to enhance tumor control in the B16 melanoma model. Oncolmmunology, 2014, 3, e29028.	2.1	11
397	Human leukocyte antigen Bw4 and Bw6 epitopes recognized by antibodies and natural killer cells. Current Opinion in Organ Transplantation, 2014, 19, 436-441.	0.8	18
398	Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag. Aids, 2014, 28, 2786-2788.	1.0	5
399	Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation. Aids, 2014, 28, 2781-2786.	1.0	20
400	Ontogeny of Innate T Lymphocytes ââ,¬â€œ Some Innate Lymphocytes are More Innate than Others. Frontiers in Immunology, 2014, 5, 486.	2.2	74
401	NK Cell Genotype and Phenotype at Diagnosis of Acute Lymphoblastic Leukemia Correlate with Postinduction Residual Disease. Clinical Cancer Research, 2014, 20, 5986-5994.	3.2	36
402	Mutational and Structural Analysis of KIR3DL1 Reveals a Lineage-Defining Allotypic Dimorphism That Impacts Both HLA and Peptide Sensitivity. Journal of Immunology, 2014, 192, 2875-2884.	0.4	48
403	Activating Killer Cell Ig-Like Receptors in Health and Disease. Frontiers in Immunology, 2014, 5, 184.	2,2	64

#	Article	IF	CITATIONS
404	Adaptations of Natural Killer Cells to Self-MHC Class I. Frontiers in Immunology, 2014, 5, 349.	2.2	25
405	The biology of <scp>NK</scp> cells and their receptors affects clinical outcomes after hematopoietic cell transplantation ( <scp>HCT</scp> ). Immunological Reviews, 2014, 258, 45-63.	2.8	83
406	Clinical Development of Antibody-Fusion Proteins for Cancer Therapy. , 2014, , 213-235.		0
407	NK cell development and function – Plasticity and redundancy unleashed. Seminars in Immunology, 2014, 26, 114-126.	2.7	46
408	<scp>NK</scp> cells gain higher <scp>IFN</scp> â€Î³ competence during terminal differentiation. European Journal of Immunology, 2014, 44, 2074-2084.	1.6	94
409	Natural Killer Cells. , 2014, , 187-199.		O
410	Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy, 2014, 16, 1453-1466.	0.3	47
411	Clinical utility of natural killer cells in cancer therapy and transplantation. Seminars in Immunology, 2014, 26, 161-172.	2.7	154
412	ADAM17-Mediated Shedding of Fc $\hat{l}^3$ RIIIA on Human NK Cells: Identification of the Cleavage Site and Relationship with Activation. Journal of Immunology, 2014, 192, 741-751.	0.4	71
413	SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells. Nature Communications, 2014, 5, 5108.	5.8	108
414	The Combination of Type I IFN, TNF- $\hat{l}\pm$ , and Cell Surface Receptor Engagement with Dendritic Cells Enables NK Cells To Overcome Immune Evasion by Dengue Virus. Journal of Immunology, 2014, 193, 5065-5075.	0.4	28
415	Expression of killer cell immunoglobulin-like receptors (KIRs) by natural killer cells during acute CMV infection after kidney transplantation. Transplant Immunology, 2014, 31, 157-164.	0.6	15
416	KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity. Journal of Immunology, 2014, 192, 5618-5624.	0.4	68
417	CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells. Cancer Immunology Research, 2014, 2, 878-889.	1.6	48
418	Human NK Cells Licensed by Killer Ig Receptor Genes Have an Altered Cytokine Program That Modifies CD4+ T Cell Function. Journal of Immunology, 2014, 193, 940-949.	0.4	28
419	How to Trigger a Killer. Advances in Immunology, 2014, 124, 137-170.	1.1	73
420	Functional NK Cell Repertoires Are Maintained through IL-2RÎ $\pm$ and Fas Ligand. Journal of Immunology, 2014, 192, 3889-3897.	0.4	20
421	Killer Immunoglobulin-like Receptors and Tumor Immunity. Cancer Immunology Research, 2014, 2, 99-104.	1.6	68

#	Article	IF	CITATIONS
422	NK cell self tolerance, responsiveness and missing self recognition. Seminars in Immunology, 2014, 26, 138-144.	2.7	160
423	The Functional Significance of Cattle Major Histocompatibility Complex Class I Genetic Diversity. Annual Review of Animal Biosciences, 2014, 2, 285-306.	3.6	30
424	Allelic polymorphism, mRNA and antigen expression of KIR2DL1 in the Chinese Han population. Human Immunology, 2014, 75, 245-249.	1.2	6
425	Impaired NKâ€eell education diminishes resistance to murine CMV infection. European Journal of Immunology, 2014, 44, 3273-3282.	1.6	14
426	Tissue-Specific Education of Decidual NK Cells. Journal of Immunology, 2015, 195, 3026-3032.	0.4	88
427	Critical roles of coâ€activation receptor <scp>DNAX</scp> accessory moleculeâ€1 in natural killer cell immunity. Immunology, 2015, 146, 369-378.	2.0	24
428	Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes. Haematologica, 2015, 100, 643-652.	1.7	51
429	Activating KIR: iN Kase of KIR-ligand mismatch. Blood, 2015, 125, 3045-3046.	0.6	2
430	Human <scp>KIR</scp> repertoires: shaped by genetic diversity and evolution. Immunological Reviews, 2015, 267, 178-196.	2.8	102
431	Selection, tuning, and adaptation in mouse <scp>NK</scp> cell education. Immunological Reviews, 2015, 267, 167-177.	2.8	34
432	Natural killer cell education does not affect the magnitude of granzyme B delivery to target cells by antibody-dependent cellular cytotoxicity. Aids, 2015, 29, 1433-1443.	1.0	12
433	Natural Killer Cell Adoptive Transfer Therapy. Cancer Journal (Sudbury, Mass), 2015, 21, 486-491.	1.0	99
434	Ly49 receptors: evolution, genetic diversity, and impact on immunity. Immunological Reviews, 2015, 267, 137-147.	2.8	54
435	Current perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptors. ImmunoTargets and Therapy, 2015, 4, 45.	2.7	14
436	Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors. Frontiers in Immunology, 2015, 6, 202.	2.2	130
437	Can Selective MHC Downregulation Explain the Specificity and Genetic Diversity of NK Cell Receptors?. Frontiers in Immunology, 2015, 6, 311.	2.2	11
438	NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Frontiers in Immunology, 2015, 6, 368.	2.2	411
439	Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory?. Frontiers in Immunology, 2015, 6, 573.	2.2	51

#	Article	IF	CITATIONS
440	NK cell function and receptor diversity in the context of HCV infection. Frontiers in Microbiology, 2015, 6, 1061.	1.5	27
441	NK Cells of Kidney Transplant Recipients Display an Activated Phenotype that Is Influenced by Immunosuppression and Pathological Staging. PLoS ONE, 2015, 10, e0132484.	1.1	42
442	Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nature Reviews Drug Discovery, 2015, 14, 487-498.	21.5	203
443	Adaptive Natural Killer Cell and Killer Cell Immunoglobulin–Like Receptor–Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 2015. 21. 1653-1662.	2.0	50
444	Dynamic Regulation of NK Cell Responsiveness. Current Topics in Microbiology and Immunology, 2015, 395, 95-114.	0.7	27
445	Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab. Transplant Immunology, 2015, 32, 29-34.	0.6	19
446	Functional Anti D94/NKG2A and Anti D94/NKG2C Autoantibodies in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 1000-1011.	2.9	21
447	Maternal uterine natural killer cells nurture fetal growth: in medio stat virtus. Trends in Molecular Medicine, 2015, 21, 60-67.	3.5	31
448	A Single Amino Acid Change in Inhibitory Killer Cell Ig-like Receptor Results in Constitutive Receptor Self-Association and Phosphorylation. Journal of Immunology, 2015, 194, 817-826.	0.4	13
449	ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors. Cancer Research, 2015, 75, 824-834.	0.4	52
450	Balancing natural killer cell activation through paired receptors. Nature Reviews Immunology, 2015, 15, 243-254.	10.6	410
451	Understanding of molecular mechanisms in natural killer cell therapy. Experimental and Molecular Medicine, 2015, 47, e141-e141.	3.2	72
452	Cattle NK Cell Heterogeneity and the Influence of MHC Class I. Journal of Immunology, 2015, 195, 2199-2206.	0.4	20
453	Prenatal Allospecific NK Cell Tolerance Hinges on Instructive Allorecognition through the Activating Receptor during Development. Journal of Immunology, 2015, 195, 1506-1516.	0.4	9
454	NK cell tolerance as the final endorsement of prenatal tolerance after in utero hematopoietic cellular transplantation. Frontiers in Pharmacology, 2015, 6, 51.	1.6	13
455	Impact of multiplicity of functional KIR-HLA compound genotypes on hepatocellular carcinoma. Oncolmmunology, 2015, 4, e983765.	2.1	6
456	KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding. Journal of Immunology, 2015, 195, 1242-1250.	0.4	11
457	Functional analysis of NK cell subsets activated by 721.221 and K562 HLA-null cells. Journal of Leukocyte Biology, 2015, 97, 761-767.	1.5	20

#	Article	IF	CITATIONS
458	Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells. Journal of Immunology, 2015, 194, 4518-4527.	0.4	81
459	Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function. Immunity, 2015, 42, 443-456.	6.6	650
460	JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Research, 2015, 75, 2187-2199.	0.4	163
461	'MHC-l-opathy'â€"unified concept for spondyloarthritis and Behçet disease. Nature Reviews Rheumatology, 2015, 11, 731-740.	3.5	183
462	Diversification and Functional Specialization of Human NK Cell Subsets. Current Topics in Microbiology and Immunology, 2015, 395, 63-93.	0.7	56
463	Newtonian cell interactions shape natural killer cell education. Immunological Reviews, 2015, 267, 197-213.	2.8	55
464	Probing Human NK Cell Biology Using Human Immune System (HIS) Mice. Current Topics in Microbiology and Immunology, 2015, 395, 191-208.	0.7	10
465	Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. Clinical and Experimental Immunology, 2015, 181, 275-285.	1.1	18
466	A Higher Frequency of NKG2A <sup>+</sup> than of NKG2A <sup>â^'</sup> NK Cells Responds to Autologous HIV-Infected CD4 Cells irrespective of Whether or Not They Coexpress KIR3DL1. Journal of Virology, 2015, 89, 9909-9919.	1.5	35
467	The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell Education. Journal of Immunology, 2015, 195, 3262-3272.	0.4	47
468	A Coevolutionary Arms Race between Hosts and Viruses Drives Polymorphism and Polygenicity of NK Cell Receptors. Molecular Biology and Evolution, 2015, 32, 2149-2160.	3.5	16
469	HLA Class I Depleted hESC as a Source of Hypoimmunogenic Cells for Tissue Engineering Applications. Tissue Engineering - Part A, 2015, 21, 2559-2571.	1.6	26
470	Role of NK cells in immunotherapy and virotherapy of solid tumors. Immunotherapy, 2015, 7, 861-882.	1.0	17
471	Microchip-Based Single-Cell Imaging Reveals That CD56dimCD57â^'KIRâ^'NKG2A+ NK Cells Have More Dynamic Migration Associated with Increased Target Cell Conjugation and Probability of Killing Compared to CD56dimCD57â^'KIRâ^'NKG2Aâ^' NK Cells. Journal of Immunology, 2015, 195, 3374-3381.	0.4	28
472	Slaying the Trojan Horse: Natural Killer Cells Exhibit Robust Anti-HIV-1 Antibody-Dependent Activation and Cytolysis against Allogeneic T Cells. Journal of Virology, 2015, 89, 97-109.	1.5	42
473	Killer Cell Immunoglobulin-Like Receptor Genes and their HLA-C Ligands in Hashimoto Thyroiditis in a Chinese Population. Endocrine Practice, 2016, 22, 935-940.	1.1	4
474	Properties of Uterine Natural Killer Cells in Human Pregnancy, Major Receptors Involved, and Routes of Trophoblast Invasion. Single Cell Biology, 2016, 05, .	0.2	0
475	NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. Stem Cells International, 2016, 2016, 1-11.	1.2	21

#	Article	IF	CITATIONS
476	The Memories of NK Cells: Innate-Adaptive Immune Intrinsic Crosstalk. Journal of Immunology Research, 2016, 2016, 1-14.	0.9	39
477	NKG2C <sup>+</sup> CD57 <sup>+</sup> Natural Killer Cell Expansion Parallels Cytomegalovirus-Specific CD8 <sup>+</sup> T Cell Evolution towards Senescence. Journal of Immunology Research, 2016, 2016, 1-8.	0.9	34
478	Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2016, 7, 144.	2.2	81
479	Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches. Frontiers in Immunology, 2016, 7, 152.	2.2	80
480	Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control. Frontiers in Immunology, 2016, 7, 166.	2.2	50
481	Human Circulating and Tissue-Resident CD56bright Natural Killer Cell Populations. Frontiers in Immunology, 2016, 7, 262.	2.2	174
482	Modulation of T-bet and Eomes during Maturation of Peripheral Blood NK Cells Does Not Depend on Licensing/Educating KIR. Frontiers in Immunology, 2016, 7, 299.	2.2	22
483	The Impact of HLA Class I-Specific Killer Cell Immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection. Frontiers in Immunology, 2016, 7, 585.	2.2	40
484	KIR and HLA Genotypes Implicated in Reduced Killer Lymphocytes Immunity Are Associated with Vogt-Koyanagi-Harada Disease. PLoS ONE, 2016, 11, e0160392.	1.1	8
485	NK Cells Expressing the Inhibitory Killer Immunoglobulin-Like Receptors (iKIR) KIR2DL1, KIR2DL3 and KIR3DL1 Are Less Likely to Be CD16+ than Their iKIR Negative Counterparts. PLoS ONE, 2016, 11, e0164517.	1.1	5
486	Hematopoietic stem cell transplantation: Improving alloreactive Bw4 donor selection by genotyping codon 86 of KIR3DL1/S1. European Journal of Immunology, 2016, 46, 1511-1517.	1.6	21
487	Functional advantage of educated KIR2DL1+ natural killer cells for anti-HIV-1 antibody-dependent activation. Clinical and Experimental Immunology, 2016, 184, 101-109.	1.1	17
488	<i><scp>HLA</scp> </i> and <i><scp>KIR</scp></i> combined genotype as new response marker for <scp>HB</scp> eAgâ€positive chronic hepatitis B patients treated with interferonâ€based combination therapy. Journal of Viral Hepatitis, 2016, 23, 652-659.	1.0	9
489	NKp80 Defines a Critical Step during Human Natural Killer Cell Development. Cell Reports, 2016, 16, 379-391.	2.9	100
490	HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-Câ^—12:02/Câ^—14:03. Cell Reports, 2016, 17, 2210-2220.	2.9	27
491	Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 63-71.	1.0	9
492	Expression of KIR2DS1 by decidual natural killer cells increases their ability to control placental HCMV infection. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 15072-15077.	3.3	81
493	Natural killer cell licensing after double cord blood transplantation is driven by the self-HLA class I molecules from the dominant cord blood. Haematologica, 2016, 101, e209-e212.	1.7	4

#	Article	IF	CITATIONS
494	Natural Killer Cells for Therapy of Leukemia. Transfusion Medicine and Hemotherapy, 2016, 43, 89-95.	0.7	36
495	The role of NK cells in HIV-1 protection: autologous, allogeneic or both?. AIDS Research and Therapy, 2016, 13, 15.	0.7	21
496	New insights on the natural killer cell repertoire from a thorough analysis of cord blood cells. Journal of Leukocyte Biology, 2016, 100, 471-479.	1.5	10
497	Emerging insights into natural killer cells in human peripheral tissues. Nature Reviews Immunology, 2016, 16, 310-320.	10.6	349
498	<i>KIR3DL1</i> Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. Journal of Clinical Oncology, 2016, 34, 2443-2451.	0.8	73
499	CD69 Deficiency Enhances the Host Response to Vaccinia Virus Infection through Altered NK Cell Homeostasis. Journal of Virology, 2016, 90, 6464-6474.	1.5	10
500	Mouse host unlicensed NK cells promote donor allogeneic bone marrow engraftment. Blood, 2016, 127, 1202-1205.	0.6	19
501	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood, 2016, 128, 297-312.	0.6	54
502	HLA-C levels impact natural killer cell subset distribution and function. Human Immunology, 2016, 77, 1147-1153.	1.2	21
503	Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective. Journal of Cellular Immunotherapy, 2016, 2, 59-68.	0.6	46
504	Bone marrow transplantation for MHC class I deficiency corrects T-cell immunity but dissociates natural killer cell repertoire formation from function. Journal of Allergy and Clinical Immunology, 2016, 138, 1733-1736.e2.	1.5	7
507	Cell-Extrinsic MHC Class I Molecule Engagement Augments Human NK Cell Education Programmed by Cell-Intrinsic MHC Class I. Immunity, 2016, 45, 280-291.	6.6	58
508	Chimeric antigen receptor-engineered primary natural killer cells: a tool to improve adoptive tumor immunotherapy. Immunotherapy, 2016, 8, 983-986.	1.0	0
509	KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells. European Journal of Immunology, 2016, 46, 185-191.	1.6	23
510	The differential impact of natural killer (NK) cell education via KIR2DL3 and KIR3DL1 on CCL4 secretion in the context of in-vitroHIV infection. Clinical and Experimental Immunology, 2016, 186, 336-346.	1.1	4
511	Teach Your NK Cells Well. Immunity, 2016, 45, 229-231.	6.6	4
512	The association between killer-cell immunoglobulin-like receptor (KIR) and KIR ligand genotypes and the likelihood of BK virus replication after kidney transplantation. Transplant International, 2016, 29, 1168-1175.	0.8	8
513	How important is NK alloreactivity and KIR in allogeneic transplantation?. Best Practice and Research in Clinical Haematology, 2016, 29, 351-358.	0.7	35

#	Article	IF	CITATIONS
514	Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion. Cancer Immunology, Immunotherapy, 2016, 65, 1047-1059.	2.0	20
515	Activating Receptors for Self-MHC Class I Enhance Effector Functions and Memory Differentiation of NK Cells during Mouse Cytomegalovirus Infection. Immunity, 2016, 45, 74-82.	6.6	28
516	Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients. Cancer Research, 2016, 76, 5326-5336.	0.4	26
517	LRBA is Essential for Allogeneic Responses in Bone Marrow Transplantation. Scientific Reports, 2016, 6, 36568.	1.6	9
518	Class I HLA haplotypes form two schools that educate NK cells in different ways. Science Immunology, 2016, 1, .	5.6	189
519	Viral inhibitors of NKG2D ligands for tumor surveillance. Expert Opinion on Therapeutic Targets, 2016, 20, 1375-1387.	1.5	4
520	Ly49C Impairs NK Cell Memory in Mouse Cytomegalovirus Infection. Journal of Immunology, 2016, 197, 128-140.	0.4	10
521	The effect of sex on immune cells in healthy aging: Elderly women have more robust natural killer lymphocytes than do elderly men. Mechanisms of Ageing and Development, 2016, 156, 25-33.	2.2	46
522	Human Lymphoid Tissues Harbor a Distinct CD69+CXCR6+ NK Cell Population. Journal of Immunology, 2016, 197, 78-84.	0.4	81
523	Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes.  Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI). Bone Marrow Transplantation, 2016, 51, 1499-1503.	1.3	8
524	Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. Clinical Cancer Research, 2016, 22, 5211-5222.	3.2	137
525	Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Immunology, 2016, 196, 1400-1411.	0.4	35
526	Clinical significance of tumor expression of major histocompatibility complex class I-related chains A and B (MICA/B) in gastric cancer patients. Oncology Reports, 2016, 35, 1309-1317.	1.2	23
527	Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncolmmunology, 2016, 5, e1093721.	2.1	17
528	Relationship of <i>NKG2C</i> Copy Number with the Distribution of Distinct Cytomegalovirus-Induced Adaptive NK Cell Subsets. Journal of Immunology, 2016, 196, 3818-3827.	0.4	75
529	KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV. Journal of Immunology, 2016, 196, 3398-3410.	0.4	108
530	A hematopoietic cell–driven mechanism involving SLAMF6 receptor, SAP adaptors and SHP-1 phosphatase regulates NK cell education. Nature Immunology, 2016, 17, 387-396.	7.0	54
531	Natural Killer Cells. Current Topics in Microbiology and Immunology, 2016, , .	0.7	5

#	Article	IF	CITATIONS
532	Retuning of Mouse NK Cells after Interference with MHC Class I Sensing Adjusts Self-Tolerance but Preserves Anticancer Response. Cancer Immunology Research, 2016, 4, 113-123.	1.6	17
533	KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A. Biology of Blood and Marrow Transplantation, 2016, 22, 220-225.	2.0	15
534	Genetic associations of killer immunoglobulin like receptors and class I human leukocyte antigens on childhood acute lymphoblastic leukemia among north Indians. Human Immunology, 2016, 77, 41-46.	1.2	28
535	Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance. Cancer Immunology, Immunotherapy, 2016, 65, 417-426.	2.0	86
536	Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection. Mucosal Immunology, 2016, 9, 159-170.	2.7	23
537	Tricking the balance: NK cells in anti-cancer immunity. Immunobiology, 2017, 222, 11-20.	0.8	163
538	Bench to bedside: NK cells and control of metastasis. Clinical Immunology, 2017, 177, 50-59.	1.4	71
539	NK cell education via nonclassical MHC and non-MHC ligands. Cellular and Molecular Immunology, 2017, 14, 321-330.	4.8	131
540	Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib. Leukemia, 2017, 31, 203-212.	3.3	11
541	Role of IL-12 in overcoming the low responsiveness of NK cells to missing self after traumatic brain injury. Clinical Immunology, 2017, 177, 87-94.	1.4	14
542	Beyond Viral Neutralization. AIDS Research and Human Retroviruses, 2017, 33, 760-764.	0.5	36
543	Targeting NK-cell checkpoints for cancer immunotherapy. Current Opinion in Immunology, 2017, 45, 73-81.	2.4	158
544	Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. Seminars in Cancer Biology, 2017, 43, 74-89.	4.3	414
545	HLA Mismatching Favoring Host-Versus-Graft NK Cell Activity Via KIR3DL1 Is Associated With Improved Outcomes Following Lung Transplantation. American Journal of Transplantation, 2017, 17, 2192-2199.	2.6	22
546	Contribution of inhibitory receptor TIGIT to NK cell education. Journal of Autoimmunity, 2017, 81, 1-12.	3.0	40
547	Partial break in tolerance of NKG2Aâ^'/LIR-1â^' single KIR+ NK cells early in the course of HLA-matched, KIR-mismatched hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 1144-1155.	1.3	3
548	Monocyte/Macrophage: NK Cell Cooperationâ€"Old Tools for New Functions. Results and Problems in Cell Differentiation, 2017, 62, 73-145.	0.2	8
549	Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcÎ <sup>3</sup> RIlla-Triggered Responses. Biology of Blood and Marrow Transplantation, 2017, 23, 398-404.	2.0	48

#	Article	lF	Citations
550	Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. Leukemia, 2017, 31, 2552-2559.	3.3	16
551	Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients. European Journal of Immunology, 2017, 47, 1051-1061.	1.6	15
552	Expression of CD226 is associated to but not required for NK cell education. Nature Communications, 2017, 8, 15627.	5.8	48
553	Markers and function of human NK cells in normal and pathological conditions. Cytometry Part B - Clinical Cytometry, 2017, 92, 100-114.	0.7	110
554	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Seminars in Immunology, 2017, 31, 64-75.	2.7	110
555	Natural killer cell-mediated immunosurveillance of human cancer. Seminars in Immunology, 2017, 31, 20-29.	2.7	240
556	Natural killer cells in HIV-1 infection and therapy. Aids, 2017, 31, 2317-2330.	1.0	90
557	Innate immune cells for immunotherapy of autoimmune and cancer disorders. International Reviews of Immunology, 2017, 36, 315-337.	1.5	16
558	NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs. Stem Cell Reports, 2017, 9, 853-867.	2.3	56
559	High-level expression and purification of soluble form of human natural killer cell receptor NKR-P1 in HEK293S GnTIâ° cells. Protein Expression and Purification, 2017, 140, 36-43.	0.6	7
560	Impact of Graft-Versus-Graft Natural Killer Cell Alloreactivity on Single Unit Dominance After Double Umbilical Cord Blood Transplantation. Transplantation, 2017, 101, 2092-2101.	0.5	6
561	GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. Cancer Research, 2017, 77, 5664-5675.	0.4	114
562	Frontline Science: A hyporesponsive subset of rat NK cells negative for Ly49s3 and NKR-P1B are precursors to the functionally mature NKR-P1B+ subset. Journal of Leukocyte Biology, 2017, 102, 1289-1298.	1.5	2
563	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Science Translational Medicine, 2017, 9, .	5.8	45
564	The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity, 2017, 47, 820-833.	6.6	485
565	LILRB receptor-mediated regulation of myeloid cell maturation and function. Cancer Immunology, Immunotherapy, 2017, 66, 1079-1087.	2.0	105
566	Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self― recognition. Immunogenetics, 2017, 69, 547-556.	1.2	30
567	Deciphering the killerâ€cell immunoglobulinâ€like receptor system at superâ€resolution for natural killer and Tâ€cell biology. Immunology, 2017, 150, 248-264.	2.0	74

#	ARTICLE	IF	CITATIONS
568	Changes in T Cells After ABO-Incompatible Liver Transplantation. Journal of Investigative Surgery, 2017, 30, 235-241.	0.6	2
569	Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 153-160.	2.0	12
570	Neutrophils can disarm NK cell response through cleavage of NKp46. Journal of Leukocyte Biology, 2017, 101, 253-259.	1.5	20
571	Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69 â^ CD56 dim cells. Journal of Allergy and Clinical Immunology, 2017, 139, 1321-1330.e4.	1.5	113
572	The HLA and KIR systemsâ€"Basic mechanisms and clinical applications. Major Histocompatibility Complex, 2017, 24, 123-133.	0.2	0
573	Recent Progress Using Pluripotent Stem Cells for Cardiac Regenerative Therapy. Circulation Journal, 2017, 81, 929-935.	0.7	13
574	The Memory Activation of NK Cells: New Methods in Cancer Immunotherapy. , 0, , .		1
575	Human Leukocyte Antigen C*12:02:02 and Killer Immunoglobulin-Like Receptor 2DL5 are Distinctly Associated with Ankylosing Spondylitis in the Taiwanese. International Journal of Molecular Sciences, 2017, 18, 1775.	1.8	4
576	Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications. Frontiers in Immunology, 2017, 8, 329.	2.2	106
577	Disarming Cellular Alarm Systems—Manipulation of Stress-Induced NKG2D Ligands by Human Herpesviruses. Frontiers in Immunology, 2017, 8, 390.	2.2	33
578	Developmental and Functional Control of Natural Killer Cells by Cytokines. Frontiers in Immunology, 2017, 8, 930.	2.2	203
579	Memory of Natural Killer Cells: A New Chance against Mycobacterium tuberculosis?. Frontiers in Immunology, 2017, 8, 967.	2.2	53
580	Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas. Frontiers in Immunology, 2017, 8, 1010.	2.2	18
581	Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity. Frontiers in Immunology, 2017, 8, 1033.	2.2	17
582	Natural Killer Cell Interactions with Classical and Non-Classical Human Leukocyte Antigen Class I in HIV-1 Infection. Frontiers in Immunology, 2017, 8, 1496.	2.2	19
583	Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 1544.	2.2	71
584	Gradual Increase of Fcî³RIIIa/CD16a Expression and Shift toward IFN-î³ Secretion during Differentiation of CD56dim Natural Killer Cells. Frontiers in Immunology, 2017, 8, 1556.	2.2	5
585	Natural Killer Cells in Antifungal Immunity. Frontiers in Immunology, 2017, 8, 1623.	2.2	55

#	Article	IF	CITATIONS
586	Endothelial cells express NKG2D ligands and desensitize antitumor NK responses. ELife, 2017, 6, .	2.8	71
587	HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric Killer Immunoglobulin-like Receptor (KIR) B motifs; Contribution of KIR B motif encoded genes to NK cell responsiveness. PLoS ONE, 2017, 12, e0185160.	1.1	15
588	Significantly enhanced lung metastasis and reduced organ NK cell functions in diet-induced obese rats. BMC Obesity, 2017, 4, 24.	3.1	19
589	Clinical Applications of Natural Killer Cells. , 0, , .		0
590	NK Cells and Cancer., 0,,.		1
591	NK Cells in Cancer Immunotherapy. , 0, , .		0
592	<i>KIR3DL1</i> / <i>HLA-B</i> Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 2268-2278.	0.8	109
593	Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. Cancer Immunology Research, 2018, 6, 467-480.	1.6	76
594	Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions. Journal of Virology, 2018, 92, .	1.5	17
595	Autologous serum collected 1â€h post-exercise enhances natural killer cell cytotoxicity. Brain, Behavior, and Immunity, 2018, 71, 81-92.	2.0	19
596	Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends in Immunology, 2018, 39, 222-239.	2.9	139
597	Genetics of Natural Killer Cells in Human Health, Disease, and Survival. Annual Review of Immunology, 2018, 36, 519-548.	9.5	86
598	Natural killer cell education in human health and disease. Current Opinion in Immunology, 2018, 50, 102-111.	2.4	102
599	Influence of zinc supplementation on immune parameters in weaned pigs. Journal of Trace Elements in Medicine and Biology, 2018, 49, 231-240.	1.5	56
600	NK cell therapy for hematologic malignancies. International Journal of Hematology, 2018, 107, 262-270.	0.7	64
601	Diversification of human NK cells: Lessons from deep profiling. Journal of Leukocyte Biology, 2018, 103, 629-641.	1.5	56
602	Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood, 2018, 131, 1053-1062.	0.6	111
603	Human NK Cells Downregulate Zap70 and Syk in Response to Prolonged Activation or DNA Damage. Journal of Immunology, 2018, 200, 1146-1158.	0.4	13

#	Article	IF	Citations
604	Haploidentical Transplants and NK Cell Alloreactivity., 2018, , 145-157.		0
605	Effect of irradiation-induced intercellular adhesion molecule-1 expression on natural killer cell-mediated cytotoxicity toward human cancer cells. Cytotherapy, 2018, 20, 715-727.	0.3	28
606	Innateâ€like <scp>CD</scp> 8+ Tâ€cells and <scp>NK</scp> cells: converging functions and phenotypes. Immunology, 2018, 154, 547-556.	2.0	29
607	Identification of novel polymorphisms and two distinct haplotype structures in dog leukocyte antigen class I genes: DLA-88, DLA-12 and DLA-64. Immunogenetics, 2018, 70, 237-255.	1.2	23
608	Anticancer cellular immunotherapies derived from umbilical cord blood. Expert Opinion on Biological Therapy, 2018, 18, 121-134.	1.4	18
609	A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D;) Tj ETQq1 1 0	.784314 r	gBT10verloc
610	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Translational Gastroenterology and Hepatology, 2018, 3, 89-89.	1.5	30
611	Epithelial-mesenchymal transition-induced metastasis could be a bait for natural killer cells. Journal of Thoracic Disease, 2018, 10, S3143-S3146.	0.6	4
612	Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives. Oncotarget, 2018, 9, 20891-20907.	0.8	33
613	NKG2A Blockade Potentiates CD8ÂT Cell Immunity Induced by Cancer Vaccines. Cell, 2018, 175, 1744-1755.e15.	13.5	241
614	Diversity of Killer Cell Immunoglobulin-Like Receptors and Disease. Clinics in Laboratory Medicine, 2018, 38, 637-653.	0.7	26
615	CD47 Expression in Natural Killer Cells Regulates Homeostasis and Modulates Immune Response to Lymphocytic Choriomeningitis Virus. Frontiers in Immunology, 2018, 9, 2985.	2.2	52
616	Natural Killer Cell Education Is Associated With a Distinct Glycolytic Profile. Frontiers in Immunology, 2018, 9, 3020.	2.2	36
617	Natural Killer Cells: Prospects in Cancer Immunotherapy. Current Immunology Reviews, 2018, 14, 100-104.	1.2	0
618	Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A. Frontiers in Immunology, 2018, 9, 2848.	2.2	27
619	The effect of anesthetic technique on $\hat{A}\mu$ -opioid receptor expression and immune cell infiltration in breast cancer. Journal of Anesthesia, 2018, 32, 792-796.	0.7	27
620	NK Cell Education in Tumor Immune Surveillance: DNAM-1/KIR Receptor Ratios as Predictive Biomarkers for Solid Tumor Outcome. Cancer Immunology Research, 2018, 6, 1537-1547.	1.6	24
621	Natural Killer Cells. , 2018, , 240-248.		0

#	Article	IF	CITATIONS
622	Natural Killer Cell IFN $\hat{i}^3$ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery. Annals of Surgical Oncology, 2018, 25, 3747-3754.	0.7	68
623	Natural killer cells and other innate lymphoid cells in cancer. Nature Reviews Immunology, 2018, 18, 671-688.	10.6	702
624	Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. Frontiers in Immunology, 2018, 9, 2041.	2.2	93
625	Role of donor HLA class I mismatch, KIRâ€igand mismatch and HLA:KIR pairings in hematological malignancy relapse after unrelated hematopoietic stem cell transplantation. Hla, 2018, 92, 42-46.	0.4	9
626	Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study. OncoImmunology, 2018, 7, e1461305.	2.1	49
627	Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. Bone Marrow Transplantation, 2018, 53, 1498-1507.	1.3	9
628	Memory responses of innate lymphocytes and parallels with T cells. Seminars in Immunopathology, 2018, 40, 343-355.	2.8	18
629	Characterization of 108 Genomic DNA Reference Materials for 11 Human Leukocyte Antigen Loci. Journal of Molecular Diagnostics, 2018, 20, 703-715.	1.2	13
630	Activating killerâ€cell immunoglobulinâ€like receptor haplotype influences clinical outcome following HLAâ€matched sibling haematopoietic stem cell transplantation. Hla, 2018, 92, 74-82.	0.4	11
631	The yinâ€yang of the interaction between myelomonocytic cells and <scp>NK</scp> cells. Scandinavian Journal of Immunology, 2018, 88, e12705.	1.3	34
632	Impact of the Variable Killer Ig-Like Receptor–Human Leukocyte Antigen Interactions on Natural Killer Cell Cytotoxicity Toward Foreign CD4 T Cells. Frontiers in Immunology, 2018, 9, 1588.	2.2	3
633	Natural Killer Cell Immunity. , 2018, , 240-246.e3.		0
634	CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells. Frontiers in Immunology, 2018, 9, 486.	2.2	91
635	Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors–Human Leukocyte Antigen Ligand Mismatch and Activation Receptor–Ligand Interactions. Frontiers in Immunology, 2018, 9, 1345.	2.2	52
636	Current strategies exploiting NKâ€cell therapy to treat haematologic malignancies. International Journal of Immunogenetics, 2018, 45, 237-246.	0.8	21
637	HLA-F on HLA-Null 721.221 Cells Activates Primary NK Cells Expressing the Activating Killer Ig-like Receptor KIR3DS1. Journal of Immunology, 2018, 201, 113-123.	0.4	14
639	Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. Retrovirology, 2018, 15, 58.	0.9	32
640	Whole Exome Sequencing of Patients from Multicase Families with Systemic Lupus Erythematosus Identifies Multiple Rare Variants. Scientific Reports, 2018, 8, 8775.	1.6	32

#	Article	IF	CITATIONS
641	Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. Nature Communications, 2018, 9, 2275.	5.8	<b>7</b> 5
642	IXA Honorary Member Lecture, 2017: The long and winding road to tolerance. Xenotransplantation, 2018, 25, e12419.	1.6	8
643	Genome-wide analyses and functional profiling of human NK cell lines. Molecular Immunology, 2019, 115, 64-75.	1.0	33
644	Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment. Cancer Immunology Research, 2019, 7, 1547-1561.	1.6	66
645	Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver International, 2019, 39, 1608-1621.	1.9	67
646	Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers, 2019, 11, 996.	1.7	28
647	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Frontiers in Immunology, 2019, 10, 1179.	2.2	269
648	Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam. International Journal of Molecular Sciences, 2019, 20, 3166.	1.8	15
649	HLA-F on Autologous HIV-Infected Cells Activates Primary NK Cells Expressing the Activating Killer Immunoglobulin-Like Receptor KIR3DS1. Journal of Virology, 2019, 93, .	1.5	20
650	Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors. Cancers, 2019, 11, 1534.	1.7	57
651	Monalizumab: inhibiting the novel immune checkpoint NKG2A. , 2019, 7, 263.		182
652	Synergized regulation of NK cell education by NKG2A and specific Ly49 family members. Nature Communications, 2019, 10, 5010.	5.8	43
653	Advances in NK cell bio. Molecular Immunology, 2019, 115, 1-2.	1.0	0
654	Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. Frontiers in Immunology, 2019, 10, 2357.	2.2	99
655	Exploiting NK Cell Surveillance Pathways for Cancer Therapy. Cancers, 2019, 11, 55.	1.7	41
656	Changes in the NK Cell Repertoire Related to Initiation of TB Treatment and Onset of Immune Reconstitution Inflammatory Syndrome in TB/HIV Co-infected Patients in Rio de Janeiro, Brazil—ANRS 12274. Frontiers in Immunology, 2019, 10, 1800.	2.2	7
657	NK cells are activated and primed for skin-homing during acute dengue virus infection in humans. Nature Communications, 2019, 10, 3897.	5.8	46
658	Imbalance of Genes Encoding Natural Killer Immunoglobulin-Like Receptors and Human Leukocyte Antigen in Patients With Biliary Cancer. Gastroenterology, 2019, 157, 1067-1080.e9.	0.6	19

#	Article	IF	Citations
659	The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells. Journal of Virology, 2019, 93, .	1.5	10
660	NK Cells in the Treatment of Hematological Malignancies. Journal of Clinical Medicine, 2019, 8, 1557.	1.0	39
661	Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells. Biomedical Journal, 2019, 42, 218-232.	1.4	24
662	NK Cell Hyporesponsiveness: More Is Not Always Better. International Journal of Molecular Sciences, 2019, 20, 4514.	1.8	19
663	Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness. Frontiers in Immunology, 2019, 10, 2164.	2.2	23
664	Natural Killer Cells in GvHD and GvL. , 2019, , 275-292.		5
665	Endoplasmic reticulum aminopeptidase 1 polymorphism lle276Met is associated with atopic dermatitis and affects the generation of an ⟨scp⟩HLA⟨ scp⟩  associated antigenic epitope ⟨i⟩in vitro⟨ i⟩. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 906-911.	1.3	8
666	Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC. Journal of Leukocyte Biology, 2019, 105, 551-563.	1.5	12
667	Remodeling of secretory lysosomes during education tunes functional potential in NK cells. Nature Communications, 2019, 10, 514.	5.8	103
668	Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5. Oncolmmunology, 2019, 8, e1534664.	2.1	25
669	Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Communications, 2019, 39, 1-16.	3.7	49
670	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer. Cancer Immunology Research, 2019, 7, 1230-1236.	1.6	59
671	Activating KIRs on Educated NK Cells Support Downregulation of CD226 and Inefficient Tumor Immunosurveillance. Cancer Immunology Research, 2019, 7, 1307-1317.	1.6	8
672	A natural killer cell receptor takes sharp aim at the world of bacteria. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12601-12603.	3.3	3
673	Decreased interferon $\hat{a} \in \hat{A}^3$ production by NK cells from KIR haplotype B carriers in hepatitis C virus infection. Liver International, 2019, 39, 1237-1245.	1.9	3
674	TNFR2 signaling modulates immunity after allogeneic hematopoietic cell transplantation. Cytokine and Growth Factor Reviews, 2019, 47, 54-61.	3.2	8
675	NK cells to cure cancer. Seminars in Immunology, 2019, 41, 101272.	2.7	70
676	NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. Cytotherapy, 2019, 21, 603-611.	0.3	15

#	Article	IF	CITATIONS
677	Natural killer cells as a promising therapeutic target for cancer immunotherapy. Archives of Pharmacal Research, 2019, 42, 591-606.	2.7	29
678	Natural killer cells: From surface receptors to the cure of highâ€risk leukemia (Ceppellini Lecture). Hla, 2019, 93, 185-194.	0.4	11
679	Characterization of human natural killer cells for therapeutic use. Cytotherapy, 2019, 21, 315-326.	0.3	5
680	NK cell recognition of hematopoietic cells by SLAM-SAP families. Cellular and Molecular Immunology, 2019, 16, 452-459.	4.8	15
681	Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function. BMC Immunology, 2019, 20, 8.	0.9	40
682	Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. British Journal of Cancer, 2019, 120, 871-882.	2.9	62
683	The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine, 2019, 117, 30-40.	1.4	156
684	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cellular and Molecular Immunology, 2019, 16, 430-441.	4.8	327
685	Memory NK Cell Features Exploitable in Anticancer Immunotherapy. Journal of Immunology Research, 2019, 2019, 1-8.	0.9	15
686	Ly49R activation receptor drives self-MHC–educated NK cell immunity against cytomegalovirus infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26768-26778.	3.3	10
687	$CD8\hat{l}\pm\hat{l}\pm$ homodimers function as a coreceptor for KIR3DL1. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17951-17956.	3.3	14
688	Genetic diversity affects the nanoscale membrane organization and signaling of natural killer cell receptors. Science Signaling, 2019, 12, .	1.6	16
689	Conserved and variable natural killer cell receptors: diverse approaches to viral infections. Immunology, 2019, 156, 319-328.	2.0	28
690	The HLA-B â^'21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood, 2019, 133, 1479-1488.	0.6	50
691	SLAM family receptors in natural killer cells – Mediators of adhesion, activation and inhibition via cis and trans interactions. Clinical Immunology, 2019, 204, 37-42.	1.4	17
692	Natural killer cells in lung transplantation. Thorax, 2019, 74, 397-404.	2.7	41
693	Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells. Journal of Allergy and Clinical Immunology, 2019, 143, 346-358.e6.	1.5	59
694	Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy. Cancers, 2020, 12, 79.	1.7	29

#	Article	IF	Citations
695	Study of KIR gene expression at the mRNA level in specific donor-derived NK cells after allogeneic HSCT. Immunogenetics, 2020, 72, 135-141.	1.2	4
696	Natural Killer Cells. , 2020, , 229-242.		1
697	High Metabolic Function and Resilience of NKG2A-Educated NK Cells. Frontiers in Immunology, 2020, 11, 559576.	2.2	13
698	Metabolism of Natural Killer Cells and Other Innate Lymphoid Cells. Frontiers in Immunology, 2020, 11, 1989.	2.2	36
699	The Genetic Mechanisms Driving Diversification of the KIR Gene Cluster in Primates. Frontiers in Immunology, 2020, 11, 582804.	2.2	15
700	HLA-A alleles influencing NK cell function impact AML relapse following allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 4955-4964.	2.5	14
701	IL-18 Responsiveness Defines Limitations in Immune Help for Specialized FcRγ–NK Cells. Journal of Immunology, 2020, 205, 3429-3442.	0.4	4
702	Centromeric KIR AA Individuals Harbor Particular KIR Alleles Conferring Beneficial NK Cell Features with Implications in Haplo-Identical Hematopoietic Stem Cell Transplantation. Cancers, 2020, 12, 3595.	1.7	11
703	Phenotypic and Functional Characterization of NK Cells in $\hat{l}\pm\hat{l}^2T$ -Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia. Cancers, 2020, 12, 2187.	1.7	19
704	Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. Journal of Immunology, 2020, 205, 1441-1448.	0.4	9
705	Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia. Cancers, 2020, 12, 1927.	1.7	15
706	Killer Cell Immunoglobulin-like Receptor Variants Are Associated with Protection from Symptoms Associated with More Severe Course in Parkinson Disease. Journal of Immunology, 2020, 205, 1323-1330.	0.4	18
707	SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway. Cells, 2020, 9, 1975.	1.8	69
708	Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 2022.	2.2	39
709	Escape of tumor cells from the NK cell cytotoxic activity. Journal of Leukocyte Biology, 2020, 108, 1339-1360.	1.5	14
710	The role of natural killer cells in Parkinson's disease. Experimental and Molecular Medicine, 2020, 52, 1517-1525.	3.2	42
711	Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia. Immunological Medicine, 2020, 44, 1-8.	1.4	7
712	Natural killer cell immunotypes related to COVID-19 disease severity. Science Immunology, 2020, 5, .	5.6	344

#	Article	IF	CITATIONS
713	Role of Natural Killer Cells in Uveal Melanoma. Cancers, 2020, 12, 3694.	1.7	16
714	Prospects for NK Cell Therapy of Sarcoma. Cancers, 2020, 12, 3719.	1.7	12
715	The Role of HLA and KIR Immunogenetics in BK Virus Infection after Kidney Transplantation. Viruses, 2020, 12, 1417.	1.5	8
716	Natural killer cell-based immunotherapy for acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 167.	6.9	55
717	Clonal expansion of innate and adaptive lymphocytes. Nature Reviews Immunology, 2020, 20, 694-707.	10.6	66
718	Natural killer cell receptor variants and chronic hepatitis B virus infection in the Vietnamese population. International Journal of Infectious Diseases, 2020, 96, 541-547.	1.5	11
719	Deciphering Natural Killer Cell Homeostasis. Frontiers in Immunology, 2020, 11, 812.	2.2	34
720	NKG2A and COVID-19: another brick in the wall. Cellular and Molecular Immunology, 2020, 17, 672-674.	4.8	72
721	NK Cell Development in Times of Innate Lymphoid Cell Diversity. Frontiers in Immunology, 2020, 11, 813.	2.2	39
722	Significance of KIR like natural killer cell receptors in autoimmune disorders. Clinical Immunology, 2020, 216, 108449.	1.4	22
723	HLAs, TCRs, and KIRs, a Triumvirate of Human Cell-Mediated Immunity. Annual Review of Biochemistry, 2020, 89, 717-739.	5.0	49
724	TRPML Cation Channels in Inflammation and Immunity. Frontiers in Immunology, 2020, 11, 225.	2.2	33
725	Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy. Cells, 2020, 9, 753.	1.8	22
726	Tuning of human NK cells by endogenous HLA-C expression. Immunogenetics, 2020, 72, 205-215.	1.2	20
727	Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 191.	2.2	30
728	Unparalleled Rapid Evolution of KIR Genes in Rhesus and Cynomolgus Macaque Populations. Journal of Immunology, 2020, 204, 1770-1786.	0.4	12
729	MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers, 2020, 12, 1760.	1.7	213
730	Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways. Molecular Therapy - Methods and Clinical Development, 2020, 18, 428-445.	1.8	42

#	Article	IF	Citations
731	Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?. Frontiers in Immunology, 2020, 11, 275.	2.2	101
732	Regulation of MHC class I-independent NK cell education by SLAM family receptors. Advances in Immunology, 2020, 145, 159-185.	1.1	3
733	NK Cell-Based Immunotherapy in Renal Cell Carcinoma. Cancers, 2020, 12, 316.	1.7	20
734	Distinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancy. Nature Communications, 2020, 11, 381.	5.8	110
735	TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells. Frontiers in Immunology, 2020, 11, 753.	2.2	13
736	Differential IL-18 Dependence of Canonical and Adaptive NK Cells for Antibody Dependent Responses to P. falciparum. Frontiers in Immunology, 2020, 11, 533.	2.2	5
737	KIR Variation in Iranians Combines High Haplotype and Allotype Diversity With an Abundance of Functional Inhibitory Receptors. Frontiers in Immunology, 2020, 11, 556.	2.2	18
738	Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?. Cancers, 2020, 12, 774.	1.7	10
739	Natural Killer Cells: Tumor Surveillance and Signaling. Cancers, 2020, 12, 952.	1.7	56
740	PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunology, Immunotherapy, 2020, 69, 1505-1517.	2.0	58
741	Mechanisms of Resistance to NK Cell Immunotherapy. Cancers, 2020, 12, 893.	1.7	34
742	Paths taken towards NK cell–mediated immunotherapy of human cancer—a personal reflection. Scandinavian Journal of Immunology, 2021, 93, e12993.	1.3	5
743	CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharmaceutica Sinica B, 2021, 11, 1129-1147.	5.7	47
744	Missing Self-Induced Activation of NK Cells Combines with Non-Complement-Fixing Donor-Specific Antibodies to Accelerate Kidney Transplant Loss in Chronic Antibody-Mediated Rejection. Journal of the American Society of Nephrology: JASN, 2021, 32, 479-494.	3.0	56
745	Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion. International Reviews of Immunology, 2021, 40, 197-216.	1.5	8
747	The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity, 2021, 54, 132-150.e9.	6.6	52
748	Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV–HCV co-infected individuals. Clinical and Experimental Immunology, 2021, 204, 107-124.	1.1	1
749	Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers. European Urology Oncology, 2021, 4, 246-255.	2.6	10

#	Article	IF	CITATIONS
750	Role of the Immune Microenvironment in SARS-CoV-2 Infection. Cell Transplantation, 2021, 30, 096368972110106.	1.2	10
752	Challenges for NK cell-based therapies: What can we learn from lymph nodes?. , 2021, , 33-51.		0
753	Lipid Metabolism in Tumor-Associated Natural Killer Cells. Advances in Experimental Medicine and Biology, 2021, 1316, 71-85.	0.8	9
<b>7</b> 54	Natural Killer Cell Therapy in Allogeneic Hematopoietic Cell Transplantation. , 2021, , 847-857.		0
755	The Current Landscape of Antibody-based Therapies in Solid Malignancies. Theranostics, 2021, 11, 1493-1512.	4.6	20
756	Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. Oncolmmunology, 2021, 10, 1936392.	2.1	14
757	SIV-induced terminally differentiated adaptive NK cells in lymph nodes associated with enhanced MHC-E restricted activity. Nature Communications, 2021, 12, 1282.	5.8	24
758	Immune Microenvironment: New Insight for Familial Adenomatous Polyposis. Frontiers in Oncology, 2021, 11, 570241.	1.3	7
759	Dual effects of natural killer cells in transplantation for leukemia. Critical Reviews in Oncology/Hematology, 2021, 158, 103206.	2.0	4
760	Adaptive Admixture of HLA Class I Allotypes Enhanced Genetically Determined Strength of Natural Killer Cells in East Asians. Molecular Biology and Evolution, 2021, 38, 2582-2596.	3.5	17
761	Natural Killer Cells: Potential Biomarkers and Therapeutic Target in Autoimmune Diseases?. Frontiers in Immunology, 2021, 12, 616853.	2.2	36
762	Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 614488.	2.2	6
763	Molecular Signatures of Natural Killer Cells in CMV-Associated Anterior Uveitis, A New Type of CMV-Induced Disease in Immunocompetent Individuals. International Journal of Molecular Sciences, 2021, 22, 3623.	1.8	5
764	The role of KIR positive NK cells in diseases and its importance in clinical intervention. International Immunopharmacology, 2021, 92, 107361.	1.7	18
765	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. Cancers, 2021, 13, 1363.	1.7	24
766	Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells. Pharmaceuticals, 2021, 14, 236.	1.7	15
767	The transcription factor $Bcl11b$ promotes both canonical and adaptive NK cell differentiation. Science Immunology, 2021, 6, .	5.6	42
768	Coexistence of inhibitory and activating killer-cell immunoglobulin-like receptors to the same cognate HLA-C2 and Bw4 ligands confer breast cancer risk. Scientific Reports, 2021, 11, 7932.	1.6	6

#	ARTICLE	IF	CITATIONS
769	Single-Cell Profiling of Kidney Transplant Recipients With Immunosuppressive Treatment Reveals the Dynamic Immune Characteristics. Frontiers in Immunology, 2021, 12, 639942.	2.2	11
770	High-Resolution Analysis Identifies High Frequency of KIR-A Haplotypes and Inhibitory Interactions of KIR With HLA Class I in Zhejiang Han. Frontiers in Immunology, 2021, 12, 640334.	2.2	6
771	Delivery technologies to engineer natural killer cells for cancer immunotherapy. Cancer Gene Therapy, 2021, 28, 947-959.	2.2	20
772	Natural Polysaccharides and Their Derivates: A Promising Natural Adjuvant for Tumor Immunotherapy. Frontiers in Pharmacology, 2021, 12, 621813.	1.6	22
773	Human NK cells, their receptors and function. European Journal of Immunology, 2021, 51, 1566-1579.	1.6	75
774	Expression of NK Cell Receptor Ligands on Leukemic Cells Is Associated with the Outcome of Childhood Acute Leukemia. Cancers, 2021, 13, 2294.	1.7	7
775	Decidual Natural Killer Cells: A Good Nanny at the Maternal-Fetal Interface During Early Pregnancy. Frontiers in Immunology, 2021, 12, 663660.	2.2	36
776	Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors. Cancers, 2021, 13, 2796.	1.7	13
777	The CD94/NKG2A inhibitory receptor educates uterine NK cells to optimize pregnancy outcomes in humans and mice. Immunity, 2021, 54, 1231-1244.e4.	6.6	44
778	Epithelial membrane protein 2 (Emp2) modulates innate immune cell population recruitment at the maternal-fetal interface. Journal of Reproductive Immunology, 2021, 145, 103309.	0.8	4
779	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. International Journal of Molecular Sciences, 2021, 22, 6665.	1.8	11
780	HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation. Frontiers in Immunology, 2021, 12, 680480.	2.2	14
781	Relevance of Polymorphic KIR and HLA Class I Genes in NK-Cell-Based Immunotherapies for Adult Leukemic Patients. Cancers, 2021, 13, 3767.	1.7	10
782	Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma., 2021, 9, e002958.		10
783	The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy. Cancers, 2021, 13, 3865.	1.7	4
784	Licensing Natural Killers for Antiviral Immunity. Pathogens, 2021, 10, 908.	1.2	5
785	Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?. Epigenomes, 2021, 5, 16.	0.8	5
786	Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy. Molecular Diagnosis and Therapy, 2021, 25, 577-592.	1.6	27

#	ARTICLE	IF	CITATIONS
787	NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data. Molecular Aspects of Medicine, 2021, 80, 100967.	2.7	7
788	Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients. Transplantation and Cellular Therapy, 2021, 27, 686.e1-686.e9.	0.6	3
789	Natural killer cells and unconventional T cells in COVID-19. Current Opinion in Virology, 2021, 49, 176-182.	2.6	28
790	Deciphering the biology of KIR2DL3+ T lymphocytes that are associated to relapse in haploidentical HSCT. Scientific Reports, 2021, 11, 15782.	1.6	3
791	KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia. ImmunoHorizons, 2021, 5, 687-702.	0.8	2
792	Killer‑cell immunoglobulin‑like receptor/human leukocyte antigen‑C combination and â€~great obstetrical syndromes' (Review). Experimental and Therapeutic Medicine, 2021, 22, 1178.	0.8	4
793	Kill and Clearance in HCC: An Approach Based on NK Cells and Macrophages. Frontiers in Oncology, 2021, 11, 693076.	1.3	2
794	HLA-G1+ Expression in GGTA1KO Pigs Suppresses Human and Monkey Anti-Pig T, B and NK Cell Responses. Frontiers in Immunology, 2021, 12, 730545.	2.2	10
795	Advances in generating HLA-Universal platelets for transfusion medicine. Journal of Immunology and Regenerative Medicine, 2021, 14, 100053.	0.2	0
796	Soluble and Exosome-Bound $\hat{I}_{\pm}$ -Galactosylceramide Mediate Preferential Proliferation of Educated NK Cells with Increased Anti-Tumor Capacity. Cancers, 2021, 13, 298.	1.7	3
797	HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf― Immunotherapy. Frontiers in Immunology, 2020, 11, 586168.	2.2	23
798	Sex- and ageâ€dependent alterations of splenic immune cell profile and NK cell phenotypes and function in C57BL/6J mice. Immunity and Ageing, 2021, 18, 3.	1.8	34
799	Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors. Vaccines, 2021, 9, 64.	2.1	11
800	Natural killer cells in inflammatory autoimmune diseases. Clinical and Translational Immunology, 2021, 10, e1250.	1.7	29
801	The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system. Immunity, Inflammation and Disease, 2017, 5, 218-232.	1.3	40
802	Cellular Adoptive Immunotherapy After Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, 2009, 144, 497-537.	0.2	5
803	CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy. Methods in Molecular Biology, 2020, 2121, 213-239.	0.4	13
804	Bridging Innate NK Cell Functions with Adaptive Immunity. Advances in Experimental Medicine and Biology, 2011, 780, 45-55.	0.8	32

#	Article	IF	CITATIONS
805	Natural Killer Cells and Killer-Cell Immunoglobulin-Like Receptor Polymorphisms: Their Role in Hematopoietic Stem Cell Transplantation. Methods in Molecular Biology, 2014, 1109, 139-158.	0.4	5
806	Analysis of the KIR Repertoire in Human NK Cells by Flow Cytometry. Methods in Molecular Biology, 2010, 612, 353-364.	0.4	24
807	Polymorphic KIR-HLA System Regulates Natural Killer Cell Response., 2016,, 369-380.		1
808	NK cells in autoimmune diseases: Linking innate and adaptive immune responses. Autoimmunity Reviews, 2018, 17, 142-154.	2.5	94
809	Single-cell RNA-seq reveals different subsets of non-specific cytotoxic cells in teleost. Genomics, 2020, 112, 5170-5179.	1.3	42
810	Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity. Seminars in Hematology, 2020, 57, 167-174.	1.8	8
815	Landscape of natural killer cell activity in head and neck squamous cell carcinoma., 2020, 8, e001523.		36
816	Footprint of the COVID-19 Pandemic in India: A Study of Immune Landscape and Other Factors Shielding Mortality. Analytical Cellular Pathology, 2020, 2020, 1-12.	0.7	2
817	Exposure to wild-type AAV drives distinct capsid immunity profiles in humans. Journal of Clinical Investigation, 2018, 128, 5267-5279.	3.9	76
818	Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. Journal of Clinical Investigation, 2008, 118, 1017-26.	3.9	141
819	Pregnancy immunogenetics: NK cell education in the womb?. Journal of Clinical Investigation, 2010, 120, 3801-3804.	3.9	32
820	When NK cells overcome their lack of education. Journal of Clinical Investigation, 2012, 122, 3053-3056.	3.9	11
821	Cognate HLA absence in trans diminishes human NK cell education. Journal of Clinical Investigation, 2016, 126, 3772-3782.	3.9	33
822	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood, 2018, 131, 247-262.	0.6	164
823	Natural killer cell regulation - beyond the receptors. F1000prime Reports, 2014, 6, 87.	5.9	34
824	Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells. PLoS ONE, 2009, 4, e8132.	1.1	36
825	Natural Killer Cell Tolerance Persists Despite Significant Reduction of Self MHC Class I on Normal Target Cells in Mice. PLoS ONE, 2010, 5, e13174.	1.1	26
826	KIR and HLA Loci Are Associated with Hepatocellular Carcinoma Development in Patients with Hepatitis B Virus Infection: A Case-Control Study. PLoS ONE, 2011, 6, e25682.	1.1	38

#	ARTICLE	IF	Citations
827	Natural Killer Cell Mediated Missing-Self Recognition Can Protect Mice from Primary Chronic Myeloid Leukemia In Vivo. PLoS ONE, 2011, 6, e27639.	1.1	14
828	Development of Allogeneic NK Cell Adoptive Transfer Therapy in Metastatic Melanoma Patients: In Vitro Preclinical Optimization Studies. PLoS ONE, 2013, 8, e57922.	1.1	27
829	Development of a Novel Multiplex PCR Assay to Detect Functional Subtypes of KIR3DL1 Alleles. PLoS ONE, 2014, 9, e99543.	1.1	36
830	Loss of Cytotoxicity and Gain of Cytokine Production in Murine Tumor-Activated NK Cells. PLoS ONE, 2014, 9, e102793.	1.1	6
831	Association of HLA Class-I and Inhibitory KIR Genotypes in Gabonese Patients Infected by Chikungunya or Dengue Type-2 Viruses. PLoS ONE, 2014, 9, e108798.	1.1	23
832	Natural Killer Cell Receptors and Cytotoxic Activity in Phosphomannomutase 2 Deficiency (PMM2-CDG). PLoS ONE, 2016, 11, e0158863.	1.1	9
833	KIR Polymorphisms Modulate Peptide-Dependent Binding to an MHC Class I Ligand with a Bw6 Motif. PLoS Pathogens, 2011, 7, e1001316.	2.1	60
834	A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. PLoS Pathogens, 2016, 12, e1005421.	2.1	67
835	Influenza Virus Targets Class I MHC-Educated NK Cells for Immunoevasion. PLoS Pathogens, 2016, 12, e1005446.	2.1	23
836	Positive and Negative Regulation by NK Cells in Cancer. Critical Reviews in Oncogenesis, 2014, 19, 57-66.	0.2	52
837	KIR2DL2 combined with HLA-C1 confers risk of hepatitis C virus-related hepatocellular carcinoma in younger patients. Oncotarget, 2018, 9, 19650-19661.	0.8	11
838	Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome. Oncotarget, 2015, 6, 34178-34190.	0.8	30
839	Natural Killer Cell Diversity in Viral Infection: Why and How Much?. Pathogens and Immunity, 2016, 1, 165.	1.4	25
840	Innate Immune Determinants of Graft-Versus-Host Disease and Bidirectional Immune Tolerance in Allogeneic Transplantation. OBM Transplantation, 2019, 3, 1-1.	0.2	2
841	Human NK cell development in hIL-7 and hIL-15 knockin NOD/SCID/IL2rgKO mice. Life Science Alliance, 2019, 2, e201800195.	1.3	41
842	In vitro education of human natural killer cells by KIR3DL1. Life Science Alliance, 2019, 2, e201900434.	1.3	7
843	Natural killer cell-based therapies. F1000 Medicine Reports, 2011, 3, 9.	2.9	33
844	Impact of Human Leukocyte Antigen Polymorphisms in Human Immunodeficiency Virus Progression in a Paediatric Cohort Infected with a Mono-phyletic Human Immunodeficiency Virus-1 Strain. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	3

#	Article	IF	CITATIONS
845	Immunotherapy in Cancer Treatment. Open Journal of Medical Microbiology, 2014, 04, 178-191.	0.1	5
846	High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors. ELife, 2017, 6, .	2.8	65
847	TIGIT blockade enhances NK cell activity against autologous HIVâ€1â€infected CD4 <sup>+</sup> T cells. Clinical and Translational Immunology, 2021, 10, e1348.	1.7	10
848	CD8+ T lymphocytes are sensitive to NKG2A/HLA-E licensing interaction: role in the survival of cancer patients. Oncolmmunology, 2021, 10, 1986943.	2.1	0
849	LIRâ€1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibodyâ€dependent cellular cytotoxicity. Clinical and Translational Immunology, 2021, 10, e1346.	1.7	8
850	The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 11385.	1.8	7
851	Perturbed NK-cell homeostasis associated with disease severity in chronic neutropenia. Blood, 2022, 139, 704-716.	0.6	10
852	Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?. Vaccines, 2021, 9, 1144.	2.1	4
853	Making a Killer: Selecting the Optimal Natural Killer Cells for Improved Immunotherapies. Frontiers in Immunology, 2021, 12, 765705.	2.2	4
854	A relevância das células natural killer (NK) e killer immunoglobulin-like receptors (KIR) no transplante de células-tronco hematopoéticas (TCTH). Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	0
855	Natural Killer-Cell Based Treatment in Hematopoetic Stem Cell Transplantation., 2010,, 413-425.		0
856	Natural Killer Cells for Adoptive Immunotherapy. , 2010, , 431-454.		0
857	Physiological and Pathological Aspects of Human NK Cells. , 0, , .		0
858	Natural Killer Cells. , 2014, , .		0
859	Maintenance and Function of Human CD8+ T Cells and NK Cells in Humanized Mice., 2014, , 181-192.		0
860	Correlation of Killer Immunoglobulin like Receptor Genes with the Rate of Cytomegalovirus Infection in Renal Transplantation Cases. Journal of Genetics and Genome Research, 2014, $1$ , .	0.3	1
861	Clinical significance of allelic polymorphism of KIRs in chronic myeloid leukemia. Major Histocompatibility Complex, 2018, 25, 187-195.	0.2	0
862	Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies. Clinical Hematology International, 2019, 1, 134-141.	0.7	2

#	Article	IF	Citations
863	DONOR KIR3DL1/RECEPTOR HLA-BW4-80I COMBINATION REDUCES ACUTE LEUKEMIA RELAPSE AFTER UMBILICAL CORD BLOOD TRANSPLANTATION WITHOUT IN VITRO T-CELL DEPLETION. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021005.	0.5	2
864	Conventional and Unconventional Lymphocytes in Immunity Against Mycobacterium tuberculosis. , 2021, , 133-168.		0
865	Single-Cell Multi-Omics Reveals Elevated Plasticity and Stem-Cell-Like Blasts Relevant to the Poor Prognosis of <i>KMT2A</i> -Rearranged Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
867	Abundant CpG-sequences in human genomes inhibit KIR3DL2-expressing NK cells. PeerJ, 2021, 9, e12258.	0.9	2
871	Differential loss of natural killer cell activity in patients with acute myocardial infarction and stable angina pectoris. International Journal of Clinical and Experimental Pathology, 2015, 8, 14667-75.	0.5	8
872	Killer Cell Immunoglobulin-Like Receptors (KIRs) Genotype and Haplotype Analysis in Iranians with Non-Melanoma Skin Cancers. Iranian Biomedical Journal, 2019, 23, 330-7.	0.4	2
874	The New Kid on the Block: HLA-C, a Key Regulator of Natural Killer Cells in Viral Immunity. Cells, 2021, 10, 3108.	1.8	6
875	Natural Killer Cells in the Malignant Niche of Multiple Myeloma. Frontiers in Immunology, 2021, 12, 816499.	2.2	14
876	High-resolution human KIR genotyping. Immunogenetics, 2022, 74, 369-379.	1.2	9
877	Phenotypic and Functional Plasticity of CXCR6+ Peripheral Blood NK Cells. Frontiers in Immunology, 2021, 12, 810080.	2.2	6
879	Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Reports Medicine, 2022, 3, 100508.	3.3	20
880	The War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?. Biomedicines, 2022, 10, 400.	1.4	5
881	NK cells require immune checkpoint receptor LILRB4/gp49B to control neurotropic Zika virus infections in mice. JCI Insight, 2022, 7, .	2.3	5
882	Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. International Immunopharmacology, 2022, 106, 108587.	1.7	15
883	Assessing the Response of Human NK Cell Subsets to Infection by Clinically Isolated Virus Strains. Methods in Molecular Biology, 2022, 2463, 205-220.	0.4	1
884	SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research. World Journal of Cardiovascular Diseases, 2022, 12, 168-190.	0.0	0
885	Practical Considerations and Workflow in Utilizing KIR Genotyping in Transplantation Medicine. Methods in Molecular Biology, 2022, 2463, 291-310.	0.4	2
888	Innate Immune Response in SARS-CoV-2 Infection. Microorganisms, 2022, 10, 501.	1.6	13

#	Article	IF	CITATIONS
889	Individualized Constellation of Killer Cell Immunoglobulin-Like Receptors and Cognate HLA Class I Ligands that Controls Natural Killer Cell Antiviral Immunity Predisposes COVID-19. Frontiers in Genetics, 2022, 13, 845474.	1.1	15
890	miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma. Molecular Therapy - Oncolytics, 2022, 25, 308-329.	2.0	12
892	Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nature Reviews Drug Discovery, 2022, 21, 559-577.	21.5	68
893	Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Molecular Immunology, 2022, 144, 58-70.	1.0	23
894	Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in <i>KMT2A</i> -rearranged leukemia. Blood, 2022, 139, 2198-2211.	0.6	37
895	NK cells - Dr. Jekyll and Mr. Hyde in autoimmune rheumatic diseases. International Immunopharmacology, 2022, 107, 108682.	1.7	6
896	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. International Journal of Molecular Sciences, 2021, 22, 13311.	1.8	54
897	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression. Journal of Immunology, 2022, 208, 492-500.	0.4	5
898	CAR-NK Cells: From Natural Basis to Design for Kill. Frontiers in Immunology, 2021, 12, 707542.	2.2	50
899	Characterization of <scp>KIR</scp> <sup>+</sup> <scp>NK</scp> cell subsets with a monoclonal antibody selectively recognizing <scp>KIR2DL1</scp> and blocking the specific interaction with <scp>HLA </scp> . Hla, 2022, , .	0.4	5
900	Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. International Immunopharmacology, 2022, 109, 108786.	1.7	7
901	Epitope characterization of a monoclonal antibody that selectively recognizes <scp>KIR2DL1</scp> allotypes. Hla, 2022, , .	0.4	3
902	The role of the maternal immune response in fetal programming. , 0, , 102-113.		0
932	The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 814334.	2.2	3
933	Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1763-1775.	2.0	15
934	Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL. Blood Advances, 2022, 6, 3756-3766.	2.5	3
935	Beyond Maternal Tolerance: Education of Uterine Natural Killer Cells by Maternal MHC Drives Fetal Growth. Frontiers in Immunology, 2022, 13, .	2.2	5
936	Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy. International Immunopharmacology, 2022, 109, 108783.	1.7	8

#	Article	IF	CITATIONS
937	Natural killer cells: unlocking new treatments for bladder cancer. Trends in Cancer, 2022, 8, 698-710.	3.8	5
938	Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment. International Review of Cell and Molecular Biology, 2022, , 65-122.	1.6	4
939	Three-dimensional spatial modelling of traffic-induced urban air pollution using the Graz Lagrangian model and GIS. Geomatica, $0$ , , $1$ - $16$ .	0.5	0
940	Natural Killer Cells in Antibody Independent and Antibody Dependent HIV Control. Frontiers in Immunology, 2022, 13, .	2.2	3
941	Natural killer cells: a promising immunotherapy for cancer. Journal of Translational Medicine, 2022, 20, .	1.8	56
942	NK Cells in Protection from HIV Infection. Viruses, 2022, 14, 1143.	1.5	3
943	Natural killer cells and acute myeloid leukemia: promises and challenges. Cancer Immunology, Immunotherapy, 2022, 71, 2849-2867.	2.0	5
944	Immunity at maternal–fetal interface: <scp>KIR</scp> / <scp>HLA</scp> (Allo)recognition*. Immunological Reviews, 2022, 308, 55-76.	2.8	10
946	Higher Dose of CD34+ cells Promotes Early Reconstitution of Natural Killer Cells and Is Associated with Better Outcomes After Unmanipulated Hematopoietic Stem Cell Transplantation for Myeloid Malignancies. Transplantation and Cellular Therapy, 2022, , .	0.6	2
947	Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis. Frontiers in Immunology, 0, 13, .	2.2	7
948	Natural killer (NK) cell pathology and reproductive failure: NK cell level, NK cell cytotoxicity, and KIR/HLA-C., 2022,, 9-25.		0
949	Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer. Cytotherapy, 2022, 24, 905-915.	0.3	11
950	Recruited and Tissue-Resident Natural Killer Cells in the Lung During Infection and Cancer. Frontiers in Immunology, $0,13,.$	2.2	7
951	Natural killer cells during acute HIV-1 infection: clues for HIV-1 prevention and therapy. Aids, 2022, 36, 1903-1915.	1.0	1
952	NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis. International Journal of Molecular Sciences, 2022, 23, 7859.	1,8	10
953	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. Pathology and Oncology Research, 0, 28, .	0.9	9
955	Implications of NKG2A in immunity and immune-mediated diseases. Frontiers in Immunology, $0,13,.$	2.2	20
957	Decreased CD57 expression of natural killer cells enhanced cytotoxicity in patients with primary sclerosing cholangitis. Frontiers in Immunology, 0, $13$ , .	2.2	5

#	Article	IF	CITATIONS
958	Actin Retrograde Flow Regulated by the Wiskott–Aldrich Syndrome Protein Drives the Natural Killer Cell Response. Cancers, 2022, 14, 3756.	1.7	2
959	Strategies to induce natural killer cell tolerance in xenotransplantation. Frontiers in Immunology, 0, 13, .	2.2	4
960	KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nature Medicine, 2022, 28, 2133-2144.	15.2	50
961	KIR-HLA gene diversities and susceptibility to lung cancer. Scientific Reports, 2022, 12, .	1.6	5
962	Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunology, Immunotherapy, 2023, 72, 797-804.	2.0	4
963	Uterine NK Cells Ace an "A―in Education: NKG2A Sets Up Crucial Functions at the Maternal–Fetal Interface. Journal of Immunology, 2022, 209, 1421-1425.	0.4	2
964	DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. Nature Communications, 2022, 13, .	5.8	6
965	Single-cell transcriptomics in bone marrow delineates CD56dimGranzymeK+ subset as intermediate stage in NK cell differentiation. Frontiers in Immunology, 0, 13, .	2.2	4
967	Mapping the interplay between NK cells and HIV: therapeutic implications. Journal of Leukocyte Biology, 2023, 113, 109-138.	1.5	1
968	Natural killer cells and type 1 innate lymphoid cells in cancer. Seminars in Immunology, 2023, 66, 101709.	2.7	9
969	MHC Class I–Dependent Shaping of the NK Cell Ly49 Receptor Repertoire Takes Place Early during Maturation in the Bone Marrow. Journal of Immunology, 2022, 209, 751-759.	0.4	0
970	KIR signaling is regulated by electrostatic interaction of its cytosolic tail with the plasma membrane despite being neutral polyampholyte. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	1
971	Association of Killer Cell Immunoglobulin-Like Receptors and Their HLA-Ligands with Type 1 Diabetes Among South Indian Population. Immunological Investigations, 2023, 52, 270-285.	1.0	1
974	COVID-19: Attacks Immune Cells and Interferences With Antigen Presentation Through MHC-Like Decoy System. Journal of Immunotherapy, 2023, 46, 75-88.	1.2	2
975	Butyrate limits human natural killer cell effector function. Scientific Reports, 2023, 13, .	1.6	10
976	Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality. Npj Vaccines, 2023, 8, .	2.9	3
977	Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	32
978	Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting Blood Reviews, 2023, 60, 101073.	2.8	9

#	Article	IF	CITATIONS
979	Non-classical HLA class I molecules and their potential role in viral infections. Human Immunology, 2023, 84, 384-392.	1.2	3
980	SHP-1 localization to the activating immune synapse promotes NK cell tolerance in MHC class I deficiency. Science Signaling, 2023, 16, .	1.6	2
1009	Nat $\tilde{A}^{1}\!\!/_{\!4}$ rliche Killerzellen. , 2023, , 93-111.		0
1010	EMT-induced immune evasion: connecting the dots from mechanisms to therapy. Clinical and Experimental Medicine, 2023, 23, 4265-4287.	1.9	2
1023	Isolation and characterization of primary NK cells and the enrichment of the KIR2DL1+ population. Methods in Cell Biology, 2024, , .	0.5	0